Amsacrine_51264-14-3_DataSheet_MedChemExpress
HSF1A_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:HSF1A is a cell–permeable activator of heat shock transcription factor 1 (HSF1).IC50 & Target: HSF1[1]In Vitro: HSF1A protects cells from stress–induced apoptosis, binds TRiC subunits and inhibits TRiC activity without perturbation of ATP hydrolysis. Genetic inactivation or depletion of the TRiC complex results in human HSF1 activation and HSF1A inhibits the direct interaction between purified TRiC and HSF1 in vitro. Moreover, fluorescence anisotropy experiments using FITC coupled to HSF1A demonstrates that HSF1A–FITC binds to a purified Tcp1 subunit of TRiC with an affinity of approximately 600 nM. This is validated qualitatively via titration of purified Tcp1 into binding reactions containing 500 nM Biotin or HSF1A–Biotin [1]. Quantification bycounting the number of cell containing aggregates as a function of the total number of cells reveals that at HSF1A concentrations as low as 2 μM, a reduced number of aggregate–containing cells are observed. The fraction of cells containing aggregates continued to decrease in a dose–dependent manner such that pretreatment with 12 μM HSF1A resulta in ~20% of the cells exhibiting aggregates visible by fluorescence microscopy [2].In Vivo: HSF1A enhances HSF1 activity, stabilizes HSF1 expression and minimizes Doxorubicin (DOX)–induced cardiac damage. WKY rats are challenged with DOX (accumulated dose: 30 mg/kgw), and DOX combined with HSF1A (100 mg/kgw/day). Supplementation with HSF1A significantly elevates cardiac functions back to the levels of the control group. HSF1A has been shown to stimulate human HSF1 nuclear translocation, elevate protein chaperone expression and ameliorate protein misfolding and cell death in aneurodegenerative disease model. The echocardiographic results show that HSF1A also alleviates DOX–induced failures in cardiac function [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Protein extracts are generated from mammalian, yeast and E. coli cultures using biotin–binding buffer (20 mM HEPES,5 mM MgCl 2, 1 mM EDTA, 100 mM KCl, 0.03% NP–40) supplemented with 1% Trition–X100 and protease inhibitors. Approximately 0.5mg of protein extract is incubated with 100 μM HSF1A–Biotin for 4 h at 4°C and HSF1A–Biotin associated proteins captured by with NeutrAvidin Agarose Resin. After washing in biotin binding buffer proteins are eluted using 50 μL biotin elution buffer (100 mM Tris,150 mM NaCl, 0.1 mM EDTA, 2 mM D–biotin), resolved on a 4–20% SDS–PAGE, and immunoblotted. For purified TRiC and Hsp70analyses, 5 nM protein is incubated in biotin–binding buffer+0.5% Triton X–100 with 100 μM biotin or 100 μM HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin. For NiNTA purified yeast Tcp1, different concentrations of Tcp1 0.5 μM, 1 mM, 2 mM, 3 mM and 4 mM in 25 mM Hepes pH 7.5, 150 mM NaCl are incubated with 0.5 μM Biotin or HSF1A–Biotin for 4 h at 4°C and captured with NeutrAvidin Resin [1].Cell Assay:[2]PC12 cells seeded into a 96–well plate (5×104 cells/well) are treated with increasing concentrations of HSF1A (2, 4, 8 andProduct Name:HSF1A Cat. No.:HY-103000CAS No.:1196723-93-9Molecular Formula:C21H19N3O2S2Molecular Weight:409.52Target:HSP Pathway:Cell Cycle/DNA Damage; Metabolic Enzyme/Protease Solubility:DMSO: ≥ 150 mg/mL12 μM) for 15 h, at which time httQ74–GFP expression is stimulated by incubation in the presence of 1 μg/mL Doxycycline for 5 d. Cell viability is assessed via the XTT viability assay[2].Animal Administration:[3]Rat[3]Ten–week–old Wistar Kyoto rats (WKY) are used. The rats are housed at a constant temperature (22°C) on a 12–h light/dark cycle with food and tap water. The animals are arranged into three groups: WKY rats (the control group), DOX rats and DOX rats treated with HSF1A. Each group contain five animals. The DOX group is injected with DOX (5 mg/kg) for 6 consecutive weeks intraperitoneal injection to achieve a cumulative dose of 30 mg/kg, which has been well documented to achieve cardiotoxicity. The small molecular HSF1 activator HSF1A (100 mg/kg/day) is injected intraperitoneally.References:[1]. Neef DW, et al. A direct regulatory interaction between chaperonin TRiC and stress–responsive transcription factor HSF1. Cell Rep. 2014 Nov 6;9(3):955–66.[2]. Neef DW, et al. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010 Jan 19;8(1):e1000291.[3]. Huang CY, et al. Doxorubicin attenuates CHIP–guarded HSF1 nuclear translocation and protein stability to trigger IGF–IIR–dependent cardiomyocyte death. Cell Death Dis. 2016 Nov 3;7(11):e2455.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
SCItop区期刊表
刊名简称刊名全称ATMOS CHEM PHYS ATMOSPHERIC CHEMISTRY AND PHYSICSB AM METEOROL SOC BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY CLIM DYNAM CLIMATE DYNAMICSCONTRIB MINERAL PETR CONTRIBUTIONS TO MINERALOGY AND PETROLOGY EARTH PLANET SC LETT EARTH AND PLANETARY SCIENCE LETTERSEARTH-SCI REV EARTH-SCIENCE REVIEWSGEOCHIM COSMOCHIM AC GEOCHIMICA ET COSMOCHIMICA ACTAGEOLOGY GEOLOGYGEOTEXT GEOMEMBRANES GEOTEXTILES AND GEOMEMBRANESJ CLIMATE JOURNAL OF CLIMATEJ PETROL JOURNAL OF PETROLOGYLIMNOL OCEANOGR LIMNOLOGY AND OCEANOGRAPHYNAT GEOSCI Nature GeosciencePALEOCEANOGRAPHY PALEOCEANOGRAPHYPRECAMBRIAN RES PRECAMBRIAN RESEARCHQUATERNARY SCI REV QUATERNARY SCIENCE REVIEWSREV GEOPHYS REVIEWS OF GEOPHYSICSGEOPHYS RES LETT GEOPHYSICAL RESEARCH LETTERSJ ATMOS SCI JOURNAL OF THE ATMOSPHERIC SCIENCESJ GEOPHYS RES JOURNAL OF GEOPHYSICAL RESEARCHJ HYDROL JOURNAL OF HYDROLOGYMON WEATHER REV MONTHLY WEATHER REVIEWANNU REV ASTRON ASTR ANNUAL REVIEW OF ASTRONOMY AND ASTROPHYSICS ASTRON ASTROPHYS REV ASTRONOMY AND ASTROPHYSICS REVIEWASTROPHYS J SUPPL S ASTROPHYSICAL JOURNAL SUPPLEMENT SERIES ASTROPHYS J ASTROPHYSICAL JOURNALACM COMPUT SURV ACM COMPUTING SURVEYSACM T GRAPHIC ACM TRANSACTIONS ON GRAPHICSACS NANO ACS NanoACTA BIOMATER Acta BiomaterialiaACTA MATER ACTA MATERIALIAADV APPL MECH ADVANCES IN APPLIED MECHANICSADV BIOCHEM ENG BIOT ADVANCES IN BIOCHEMICAL ENGINEERING / BIOTECHNOL ADV FUNCT MATER ADVANCED FUNCTIONAL MATERIALSADV MATER ADVANCED MATERIALSANNU REV BIOMED ENG ANNUAL REVIEW OF BIOMEDICAL ENGINEERINGANNU REV MATER RES ANNUAL REVIEW OF MATERIALS RESEARCHAPPL SPECTROSC REV APPLIED SPECTROSCOPY REVIEWSARTIF INTELL ARTIFICIAL INTELLIGENCEBIOMATERIALS BIOMATERIALSBIORESOURCE TECHNOL BIORESOURCE TECHNOLOGYBIOSENS BIOELECTRON BIOSENSORS & BIOELECTRONICSBIOTECHNOL ADV BIOTECHNOLOGY ADVANCESBIOTECHNOL BIOENG BIOTECHNOLOGY AND BIOENGINEERINGBIOTECHNOL BIOFUELS Biotechnology for BiofuelsCARBON CARBONCHEM MATER CHEMISTRY OF MATERIALSCOMPUT INTELL COMPUTATIONAL INTELLIGENCECRIT REV BIOTECHNOL CRITICAL REVIEWS IN BIOTECHNOLOGYCRIT REV FOOD SCI CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION CURR OPIN BIOTECH CURRENT OPINION IN BIOTECHNOLOGY ELECTROCHEM COMMUN ELECTROCHEMISTRY COMMUNICATIONSHUM-COMPUT INTERACT HUMAN-COMPUTER INTERACTIONIEEE J SEL AREA COMM IEEE JOURNAL ON SELECTED AREAS IN COMMUNICATIONS IEEE SIGNAL PROC MAG IEEE SIGNAL PROCESSING MAGAZINEIEEE T EVOLUT COMPUT IEEE TRANSACTIONS ON EVOLUTIONARY COMPUTATION IEEE T IND ELECTRON IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS IEEE T NEURAL NETWOR IEEE TRANSACTIONS ON NEURAL NETWORKSIEEE T PATTERN ANAL IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHIN IEEE T SOFTWARE ENG IEEE TRANSACTIONS ON SOFTWARE ENGINEERINGINT J COMPUT VISION INTERNATIONAL JOURNAL OF COMPUTER VISIONINT J HYDROGEN ENERG INTERNATIONAL JOURNAL OF HYDROGEN ENERGYINT J NONLIN SCI NUM INTERNATIONAL JOURNAL OF NONLINEAR SCIENCES AND INT J PLASTICITY INTERNATIONAL JOURNAL OF PLASTICITYINT MATER REV INTERNATIONAL MATERIALS REVIEWSJ CATAL JOURNAL OF CATALYSISJ HAZARD MATER JOURNAL OF HAZARDOUS MATERIALSJ MATER CHEM JOURNAL OF MATERIALS CHEMISTRYJ MECH BEHAV BIOMED Journal of the Mechanical Behavior of Biomedical J NEURAL ENG Journal of Neural EngineeringJ POWER SOURCES JOURNAL OF POWER SOURCESJ WEB SEMANT Journal of Web SemanticsLAB CHIP LAB ON A CHIPMACROMOL RAPID COMM MACROMOLECULAR RAPID COMMUNICATIONS MACROMOLECULES MACROMOLECULESMAT SCI ENG R MATERIALS SCIENCE & ENGINEERING R-REPORTS MATER TODAY Materials TodayMED IMAGE ANAL MEDICAL IMAGE ANALYSISMETAB ENG METABOLIC ENGINEERINGMIS QUART MIS QUARTERLYMOL NUTR FOOD RES MOLECULAR NUTRITION & FOOD RESEARCHMRS BULL MRS BULLETINNANO LETT NANO LETTERSNANO TODAY Nano TodayNANOMED-NANOTECHNOL Nanomedicine-Nanotechnology Biology and Medicine NANOTECHNOLOGY NANOTECHNOLOGYNAT BIOTECHNOL NATURE BIOTECHNOLOGYNAT MATER NATURE MATERIALSNAT NANOTECHNOL Nature NanotechnologyORG ELECTRON ORGANIC ELECTRONICSP IEEE PROCEEDINGS OF THE IEEEPLASMONICS PlasmonicsPOLYM REV Polymer ReviewsPROG CRYST GROWTH CH PROGRESS IN CRYSTAL GROWTH AND CHARACTERIZATION PROG ENERG COMBUST PROGRESS IN ENERGY AND COMBUSTION SCIENCEPROG MATER SCI PROGRESS IN MATERIALS SCIENCEPROG PHOTOVOLTAICS PROGRESS IN PHOTOVOLTAICSPROG QUANT ELECTRON PROGRESS IN QUANTUM ELECTRONICSPROG SURF SCI PROGRESS IN SURFACE SCIENCERENEW SUST ENERG REV RENEWABLE & SUSTAINABLE ENERGY REVIEWSSMALL SMALLSOFT MATTER Soft MatterTRENDS BIOTECHNOL TRENDS IN BIOTECHNOLOGYTRENDS FOOD SCI TECH TRENDS IN FOOD SCIENCE & TECHNOLOGYVLDB J VLDB JOURNALAICHE J AICHE JOURNALAPPL MICROBIOL BIOT APPLIED MICROBIOLOGY AND BIOTECHNOLOGYCHEM ENG SCI CHEMICAL ENGINEERING SCIENCEELECTROCHIM ACTA ELECTROCHIMICA ACTAFOOD CHEM FOOD CHEMISTRYIEEE T ANTENN PROPAG IEEE TRANSACTIONS ON ANTENNAS AND PROPAGATION IEEE T AUTOMAT CONTR IEEE TRANSACTIONS ON AUTOMATIC CONTROLIEEE T INFORM THEORY IEEE TRANSACTIONS ON INFORMATION THEORYIEEE T MICROW THEORY IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNI IEEE T SIGNAL PROCES IEEE TRANSACTIONS ON SIGNAL PROCESSINGIND ENG CHEM RES INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCHINT J HEAT MASS TRAN INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER J AM CERAM SOC JOURNAL OF THE AMERICAN CERAMIC SOCIETYJ ELECTROCHEM SOC JOURNAL OF THE ELECTROCHEMICAL SOCIETYJ MEMBRANE SCI JOURNAL OF MEMBRANE SCIENCEMATER LETT MATERIALS LETTERSSCRIPTA MATER SCRIPTA MATERIALIASENSOR ACTUAT B-CHEM SENSORS AND ACTUATORS B-CHEMICALSURF COAT TECH SURFACE & COATINGS TECHNOLOGYSYNTHETIC MET SYNTHETIC METALSTHIN SOLID FILMS THIN SOLID FILMSJ OPER MANAG JOURNAL OF OPERATIONS MANAGEMENTMANAGE SCI MANAGEMENT SCIENCEOMEGA-INT J MANAGE S OMEGA-INTERNATIONAL JOURNAL OF MANAGEMENT SCIENC PROD OPER MANAG PRODUCTION AND OPERATIONS MANAGEMENTEUR J OPER RES EUROPEAN JOURNAL OF OPERATIONAL RESEARCH ACCOUNTS CHEM RES ACCOUNTS OF CHEMICAL RESEARCHACTA CRYSTALLOGR A ACTA CRYSTALLOGRAPHICA SECTION AALDRICHIM ACTA ALDRICHIMICA ACTAANGEW CHEM INT EDIT ANGEWANDTE CHEMIE-INTERNATIONAL EDITIONANNU REV PHYS CHEM ANNUAL REVIEW OF PHYSICAL CHEMISTRYCATAL REV CATALYSIS REVIEWS-SCIENCE AND ENGINEERINGCHEM REV CHEMICAL REVIEWSCHEM SOC REV CHEMICAL SOCIETY REVIEWSCOORDIN CHEM REV COORDINATION CHEMISTRY REVIEWSENERG ENVIRON SCI Energy & Environmental ScienceINT REV PHYS CHEM INTERNATIONAL REVIEWS IN PHYSICAL CHEMISTRYJ AM CHEM SOC JOURNAL OF THE AMERICAN CHEMICAL SOCIETYJ PHOTOCH PHOTOBIO C JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY C-PHO NAT PROD REP NATURAL PRODUCT REPORTSPROG POLYM SCI PROGRESS IN POLYMER SCIENCESURF SCI REP SURFACE SCIENCE REPORTSTRAC-TREND ANAL CHEM TRAC-TRENDS IN ANALYTICAL CHEMISTRYANAL CHEM ANALYTICAL CHEMISTRYJ ORG CHEM JOURNAL OF ORGANIC CHEMISTRYJ PHYS CHEM B JOURNAL OF PHYSICAL CHEMISTRY BLANGMUIR LANGMUIRAPPL CATAL B-ENVIRON APPLIED CATALYSIS B-ENVIRONMENTALB AM MUS NAT HIST BULLETIN OF THE AMERICAN MUSEUM OF NATURAL HISTO CRIT REV ENV SCI TEC CRITICAL REVIEWS IN ENVIRONMENTAL SCIENCE AND TE ECOL LETT ECOLOGY LETTERSECOL MONOGR ECOLOGICAL MONOGRAPHSECOLOGY ECOLOGYENVIRON HEALTH PERSP ENVIRONMENTAL HEALTH PERSPECTIVESENVIRON MICROBIOL ENVIRONMENTAL MICROBIOLOGYEVOLUTION EVOLUTIONFRONT ECOL ENVIRON FRONTIERS IN ECOLOGY AND THE ENVIRONMENT GLOBAL CHANGE BIOL GLOBAL CHANGE BIOLOGYGLOBAL ECOL BIOGEOGR GLOBAL ECOLOGY AND BIOGEOGRAPHYISME J ISME JournalATMOS ENVIRON ATMOSPHERIC ENVIRONMENTCHEMOSPHERE CHEMOSPHEREENVIRON SCI TECHNOL ENVIRONMENTAL SCIENCE & TECHNOLOGYWATER RES WATER RESEARCHADV AGRON ADVANCES IN AGRONOMYAGR FOREST METEOROL AGRICULTURAL AND FOREST METEOROLOGYATLA-ALTERN LAB ANIM ATLA-ALTERNATIVES TO LABORATORY ANIMALSEUR J SOIL SCI EUROPEAN JOURNAL OF SOIL SCIENCEFISH FISH FISH AND FISHERIESFISH OCEANOGR FISHERIES OCEANOGRAPHYFISH SHELLFISH IMMUN FISH & SHELLFISH IMMUNOLOGYFOOD BIOPROCESS TECH Food and Bioprocess TechnologyGEODERMA GEODERMAILAR J ILAR JOURNALJ AGR FOOD CHEM JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRYJ ANIM SCI JOURNAL OF ANIMAL SCIENCEJ DAIRY SCI JOURNAL OF DAIRY SCIENCEMOL BREEDING MOLECULAR BREEDINGREV FISH BIOL FISHER REVIEWS IN FISH BIOLOGY AND FISHERIESSOIL BIOL BIOCHEM SOIL BIOLOGY & BIOCHEMISTRYSOIL SCI SOC AM J SOIL SCIENCE SOCIETY OF AMERICA JOURNALTREE PHYSIOL TREE PHYSIOLOGYVET MICROBIOL VETERINARY MICROBIOLOGYVET RES VETERINARY RESEARCHAQUACULTURE AQUACULTURECAN J FISH AQUAT SCI CANADIAN JOURNAL OF FISHERIES AND AQUATIC SCIENC FOREST ECOL MANAG FOREST ECOLOGY AND MANAGEMENTJAVMA-J AM VET MED A JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL PLANT SOIL PLANT AND SOILAM J BIOETHICS AMERICAN JOURNAL OF BIOETHICSECONOMETRICA ECONOMETRICAJ ECONOMETRICS JOURNAL OF ECONOMETRICSAM J HUM GENET AMERICAN JOURNAL OF HUMAN GENETICSANNU REV BIOCHEM ANNUAL REVIEW OF BIOCHEMISTRYANNU REV BIOPH BIOM ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STR ANNU REV BIOPHYS Annual Review of BiophysicsANNU REV CELL DEV BI ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY ANNU REV ECOL EVOL S ANNUAL REVIEW OF ECOLOGY EVOLUTION AND SYSTEMATI ANNU REV ENTOMOL ANNUAL REVIEW OF ENTOMOLOGYANNU REV GENET ANNUAL REVIEW OF GENETICSANNU REV GENOM HUM G ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS ANNU REV MICROBIOL ANNUAL REVIEW OF MICROBIOLOGYANNU REV PHYTOPATHOL ANNUAL REVIEW OF PHYTOPATHOLOGYANNU REV PLANT BIOL ANNUAL REVIEW OF PLANT BIOLOGYCELL CELLCELL HOST MICROBE Cell Host & MicrobeCELL METAB Cell MetabolismCELL STEM CELL Cell Stem CellCRIT REV BIOCHEM MOL CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR B CURR BIOL CURRENT BIOLOGYCURR OPIN CELL BIOL CURRENT OPINION IN CELL BIOLOGYCURR OPIN GENET DEV CURRENT OPINION IN GENETICS & DEVELOPMENTCURR OPIN PLANT BIOL CURRENT OPINION IN PLANT BIOLOGYCURR OPIN STRUC BIOL CURRENT OPINION IN STRUCTURAL BIOLOGYDEV CELL DEVELOPMENTAL CELLGENE DEV GENES & DEVELOPMENTGENOME RES GENOME RESEARCHJ CELL BIOL JOURNAL OF CELL BIOLOGYMICROBIOL MOL BIOL R MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWSMOL CELL MOLECULAR CELLMOL SYST BIOL Molecular Systems BiologyNAT CELL BIOL NATURE CELL BIOLOGYNAT CHEM BIOL Nature Chemical BiologyNAT GENET NATURE GENETICSNAT METHODS NATURE METHODSNAT REV GENET NATURE REVIEWS GENETICSNAT REV MICROBIOL NATURE REVIEWS MICROBIOLOGYNAT REV MOL CELL BIO NATURE REVIEWS MOLECULAR CELL BIOLOGYNAT STRUCT MOL BIOL NATURE STRUCTURAL & MOLECULAR BIOLOGYPLANT CELL PLANT CELLPLOS BIOL PLOS BIOLOGYPLOS GENET PLoS GeneticsPLOS PATHOG PLoS PathogensPROG LIPID RES PROGRESS IN LIPID RESEARCHQ REV BIOPHYS QUARTERLY REVIEWS OF BIOPHYSICSTRENDS BIOCHEM SCI TRENDS IN BIOCHEMICAL SCIENCESTRENDS CELL BIOL TRENDS IN CELL BIOLOGYTRENDS ECOL EVOL TRENDS IN ECOLOGY & EVOLUTIONTRENDS GENET TRENDS IN GENETICSTRENDS PLANT SCI TRENDS IN PLANT SCIENCEAPPL ENVIRON MICROB APPLIED AND ENVIRONMENTAL MICROBIOLOGY BIOCHEM J BIOCHEMICAL JOURNALBIOPHYS J BIOPHYSICAL JOURNALDEVELOPMENT DEVELOPMENTEMBO J EMBO JOURNALJ BACTERIOL JOURNAL OF BACTERIOLOGYJ BIOL CHEM JOURNAL OF BIOLOGICAL CHEMISTRYJ MOL BIOL JOURNAL OF MOLECULAR BIOLOGYMOL CELL BIOL MOLECULAR AND CELLULAR BIOLOGYNUCLEIC ACIDS RES NUCLEIC ACIDS RESEARCHPLANT PHYSIOL PLANT PHYSIOLOGYACTA MATH-DJURSHOLM ACTA MATHEMATICAANN MATH ANNALS OF MATHEMATICSANN STAT ANNALS OF STATISTICSB AM MATH SOC BULLETIN OF THE AMERICAN MATHEMATICAL SOCIETY COMMUN PUR APPL MATH COMMUNICATIONS ON PURE AND APPLIED MATHEMATICS FOUND COMPUT MATH FOUNDATIONS OF COMPUTATIONAL MATHEMATICS INVENT MATH INVENTIONES MATHEMATICAEINVERSE PROBL INVERSE PROBLEMSJ AM MATH SOC JOURNAL OF THE AMERICAN MATHEMATICAL SOCIETYJ AM STAT ASSOC JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION J R STAT SOC B JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES MATH MOD METH APPL S MATHEMATICAL MODELS & METHODS IN APPLIED SCIENCE MATH PROGRAM MATHEMATICAL PROGRAMMINGMEM AM MATH SOC MEMOIRS OF THE AMERICAN MATHEMATICAL SOCIETY MULTISCALE MODEL SIM MULTISCALE MODELING & SIMULATIONMULTIVAR BEHAV RES MULTIVARIATE BEHAVIORAL RESEARCHNONLINEAR ANAL-REAL NONLINEAR ANALYSIS-REAL WORLD APPLICATIONSRISK ANAL RISK ANALYSISSIAM REV SIAM REVIEWSTAT SCI STATISTICAL SCIENCESTRUCT EQU MODELING STRUCTURAL EQUATION MODELING-A MULTIDISCIPLINARY FUZZY SET SYST FUZZY SETS AND SYSTEMSJ COMPUT APPL MATH JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS J DIFFER EQUATIONS JOURNAL OF DIFFERENTIAL EQUATIONSJ MATH ANAL APPL JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONNONLINEAR ANAL-THEOR NONLINEAR ANALYSIS-THEORY METHODS & APPLICATIONS SIAM J NUMER ANAL SIAM JOURNAL ON NUMERICAL ANALYSISSIAM J SCI COMPUT SIAM JOURNAL ON SCIENTIFIC COMPUTINGACTA CRYSTALLOGR A ACTA CRYSTALLOGRAPHICA SECTION AADV PHYS ADVANCES IN PHYSICSANNU REV FLUID MECH ANNUAL REVIEW OF FLUID MECHANICSANNU REV NUCL PART S ANNUAL REVIEW OF NUCLEAR AND PARTICLE SCIENCE CRIT REV SOLID STATE CRITICAL REVIEWS IN SOLID STATE AND MATERIALS SC J HIGH ENERGY PHYS JOURNAL OF HIGH ENERGY PHYSICSLASER PHOTONICS REV Laser & Photonics ReviewsLIVING REV RELATIV Living Reviews in RelativityMASS SPECTROM REV MASS SPECTROMETRY REVIEWSNAT PHOTONICS Nature PhotonicsNAT PHYS Nature PhysicsPHYS REP PHYSICS REPORTS-REVIEW SECTION OF PHYSICS LETTER PHYS REV LETT PHYSICAL REVIEW LETTERSPROG NUCL MAG RES SP PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSC REP PROG PHYS REPORTS ON PROGRESS IN PHYSICSREV MOD PHYS REVIEWS OF MODERN PHYSICSAPPL PHYS LETT APPLIED PHYSICS LETTERSJ CHEM PHYS JOURNAL OF CHEMICAL PHYSICSPHYS REV B PHYSICAL REVIEW BPHYS REV D PHYSICAL REVIEW DADV DRUG DELIVER REV ADVANCED DRUG DELIVERY REVIEWSADV IMMUNOL ADVANCES IN IMMUNOLOGYAM J CLIN NUTR AMERICAN JOURNAL OF CLINICAL NUTRITIONAM J GASTROENTEROL AMERICAN JOURNAL OF GASTROENTEROLOGYAM J PSYCHIAT AMERICAN JOURNAL OF PSYCHIATRYAM J RESP CRIT CARE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CAR AM J TRANSPLANT AMERICAN JOURNAL OF TRANSPLANTATIONANN INTERN MED ANNALS OF INTERNAL MEDICINEANN NEUROL ANNALS OF NEUROLOGYANN RHEUM DIS ANNALS OF THE RHEUMATIC DISEASESANN SURG ANNALS OF SURGERYANNU REV IMMUNOL ANNUAL REVIEW OF IMMUNOLOGYANNU REV MED ANNUAL REVIEW OF MEDICINEANNU REV NEUROSCI ANNUAL REVIEW OF NEUROSCIENCEANNU REV NUTR ANNUAL REVIEW OF NUTRITIONANNU REV PATHOL-MECH Annual Review of Pathology-Mechanisms of Disease ANNU REV PHARMACOL ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY ANNU REV PHYSIOL ANNUAL REVIEW OF PHYSIOLOGYANNU REV PSYCHOL ANNUAL REVIEW OF PSYCHOLOGYANNU REV PUBL HEALTH ANNUAL REVIEW OF PUBLIC HEALTHARCH GEN PSYCHIAT ARCHIVES OF GENERAL PSYCHIATRYARCH INTERN MED ARCHIVES OF INTERNAL MEDICINEARTERIOSCL THROM VAS ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY ARTHRITIS RHEUM-US ARTHRITIS AND RHEUMATISMBBA-REV CANCER BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER BEHAV BRAIN SCI BEHAVIORAL AND BRAIN SCIENCESBIOL PSYCHIAT BIOLOGICAL PSYCHIATRYBLOOD BLOODBLOOD REV BLOOD REVIEWSBRAIN BRAINBRAIN RES REV BRAIN RESEARCH REVIEWSBRIT MED J BRITISH MEDICAL JOURNALCA-CANCER J CLIN CA-A CANCER JOURNAL FOR CLINICIANSCAN MED ASSOC J CANADIAN MEDICAL ASSOCIATION JOURNALCANCER CELL CANCER CELLCANCER METAST REV CANCER AND METASTASIS REVIEWSCANCER RES CANCER RESEARCHCEREB CORTEX CEREBRAL CORTEXCIRC RES CIRCULATION RESEARCHCIRCULATION CIRCULATIONCLIN CANCER RES CLINICAL CANCER RESEARCHCLIN INFECT DIS CLINICAL INFECTIOUS DISEASESCLIN MICROBIOL REV CLINICAL MICROBIOLOGY REVIEWSCLIN PHARMACOL THER CLINICAL PHARMACOLOGY & THERAPEUTICSCRIT CARE MED CRITICAL CARE MEDICINECURR OPIN IMMUNOL CURRENT OPINION IN IMMUNOLOGYCURR OPIN LIPIDOL CURRENT OPINION IN LIPIDOLOGYCURR OPIN NEUROBIOL CURRENT OPINION IN NEUROBIOLOGYCURR OPIN PHARMACOL CURRENT OPINION IN PHARMACOLOGYDIABETES DIABETESDIABETES CARE DIABETES CAREDIABETOLOGIA DIABETOLOGIADRUG DISCOV TODAY DRUG DISCOVERY TODAYDRUG RESIST UPDATE DRUG RESISTANCE UPDATESEMERG INFECT DIS EMERGING INFECTIOUS DISEASESENDOCR REV ENDOCRINE REVIEWSEPIDEMIOL REV EPIDEMIOLOGIC REVIEWSEUR HEART J EUROPEAN HEART JOURNALEUR UROL EUROPEAN UROLOGYFRONT NEUROENDOCRIN FRONTIERS IN NEUROENDOCRINOLOGY GASTROENTEROLOGY GASTROENTEROLOGYGASTROINTEST ENDOSC GASTROINTESTINAL ENDOSCOPYGUT GUTHEPATOLOGY HEPATOLOGYHUM MUTAT HUMAN MUTATIONHUM REPROD UPDATE HUMAN REPRODUCTION UPDATEHYPERTENSION HYPERTENSIONIMMUNITY IMMUNITYIMMUNOL REV IMMUNOLOGICAL REVIEWSJ ALLERGY CLIN IMMUN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYJ AM COLL CARDIOL JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGYJ AM SOC NEPHROL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGYJ AUTOIMMUN JOURNAL OF AUTOIMMUNITYJ BONE MINER RES JOURNAL OF BONE AND MINERAL RESEARCHJ CLIN INVEST JOURNAL OF CLINICAL INVESTIGATIONJ CLIN ONCOL JOURNAL OF CLINICAL ONCOLOGYJ EXP MED JOURNAL OF EXPERIMENTAL MEDICINEJ HEPATOL JOURNAL OF HEPATOLOGYJ NATL CANCER I JOURNAL OF THE NATIONAL CANCER INSTITUTEJ NEUROSCI JOURNAL OF NEUROSCIENCEJ NUCL MED JOURNAL OF NUCLEAR MEDICINEJAMA-J AM MED ASSOC JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LANCET LANCETLANCET INFECT DIS LANCET INFECTIOUS DISEASESLANCET NEUROL LANCET NEUROLOGYLANCET ONCOL LANCET ONCOLOGYLEUKEMIA LEUKEMIAMED RES REV MEDICINAL RESEARCH REVIEWSMOL ASPECTS MED MOLECULAR ASPECTS OF MEDICINEMOL PSYCHIATR MOLECULAR PSYCHIATRYNAT CLIN PRACT ONCOL Nature Clinical Practice OncologyNAT IMMUNOL NATURE IMMUNOLOGYNAT MED NATURE MEDICINENAT NEUROSCI NATURE NEUROSCIENCENAT REV CANCER NATURE REVIEWS CANCERNAT REV DRUG DISCOV NATURE REVIEWS DRUG DISCOVERYNAT REV IMMUNOL NATURE REVIEWS IMMUNOLOGYNAT REV NEUROSCI NATURE REVIEWS NEUROSCIENCENEUROLOGY NEUROLOGYNEURON NEURONNEUROPSYCHOPHARMACOL NEUROPSYCHOPHARMACOLOGYNEUROSCI BIOBEHAV R NEUROSCIENCE AND BIOBEHAVIORAL REVIEWSNEW ENGL J MED NEW ENGLAND JOURNAL OF MEDICINEOBES REV Obesity ReviewsONCOGENE ONCOGENEPHARMACOL REV PHARMACOLOGICAL REVIEWSPHARMACOL THERAPEUT PHARMACOLOGY & THERAPEUTICSPHYSIOL REV PHYSIOLOGICAL REVIEWSPHYSIOLOGY PHYSIOLOGYPLOS MED PLOS MEDICINEPROG NEUROBIOL PROGRESS IN NEUROBIOLOGYPROG RETIN EYE RES PROGRESS IN RETINAL AND EYE RESEARCHPSYCHOL BULL PSYCHOLOGICAL BULLETINPSYCHOL REV PSYCHOLOGICAL REVIEWREV MED VIROL REVIEWS IN MEDICAL VIROLOGYSCHIZOPHRENIA BULL SCHIZOPHRENIA BULLETINSEMIN CANCER BIOL SEMINARS IN CANCER BIOLOGYSEMIN IMMUNOL SEMINARS IN IMMUNOLOGYSTEM CELLS STEM CELLSSTROKE STROKETHORAX THORAXTRENDS COGN SCI TRENDS IN COGNITIVE SCIENCESTRENDS ENDOCRIN MET TRENDS IN ENDOCRINOLOGY AND METABOLISMTRENDS IMMUNOL TRENDS IN IMMUNOLOGYTRENDS MOL MED TRENDS IN MOLECULAR MEDICINETRENDS NEUROSCI TRENDS IN NEUROSCIENCESTRENDS PHARMACOL SCI TRENDS IN PHARMACOLOGICAL SCIENCESWHO TECH REP SER WHO TECHNICAL REPORT SERIESAM J CARDIOL AMERICAN JOURNAL OF CARDIOLOGYAM J EPIDEMIOL AMERICAN JOURNAL OF EPIDEMIOLOGYAM J PATHOL AMERICAN JOURNAL OF PATHOLOGYAM J PHYSIOL-HEART C AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULA ANTIMICROB AGENTS CH ANTIMICROBIAL AGENTS AND CHEMOTHERAPYBRIT J CANCER BRITISH JOURNAL OF CANCERCANCER-AM CANCER SOC CANCERCHEST CHESTCNS NEUROL DISORD-DR CNS & Neurological Disorders-Drug Targets ENDOCRINOLOGY ENDOCRINOLOGYEUR J NEUROSCI EUROPEAN JOURNAL OF NEUROSCIENCEFREE RADICAL BIO MED FREE RADICAL BIOLOGY AND MEDICINEINFECT IMMUN INFECTION AND IMMUNITYINT J CANCER INTERNATIONAL JOURNAL OF CANCERINT J RADIAT ONCOL INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOL INVEST OPHTH VIS SCI INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCEJ APPL PHYSIOL JOURNAL OF APPLIED PHYSIOLOGYJ CLIN ENDOCR METAB JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM J CLIN MICROBIOL JOURNAL OF CLINICAL MICROBIOLOGYJ COMP NEUROL JOURNAL OF COMPARATIVE NEUROLOGYJ IMMUNOL JOURNAL OF IMMUNOLOGYJ INFECT DIS JOURNAL OF INFECTIOUS DISEASESJ MED CHEM JOURNAL OF MEDICINAL CHEMISTRYJ NEUROCHEM JOURNAL OF NEUROCHEMISTRYJ NEUROPHYSIOL JOURNAL OF NEUROPHYSIOLOGYJ NUTR JOURNAL OF NUTRITIONJ PHARMACOL EXP THER JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPE J PHYSIOL-LONDON JOURNAL OF PHYSIOLOGY-LONDONJ UROLOGY JOURNAL OF UROLOGYJ VIROL JOURNAL OF VIROLOGYKIDNEY INT KIDNEY INTERNATIONALNEUROIMAGE NEUROIMAGENEUROSCIENCE NEUROSCIENCEPEDIATRICS PEDIATRICSRADIOLOGY RADIOLOGYTRANSPLANTATION TRANSPLANTATIONVIROLOGY VIROLOGYNATURE NATUREP NATL ACAD SCI USA PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES SCIENCE SCIENCEANN NY ACAD SCI ANNALS OF THE NEW YORK ACADEMY OF SCIENCESISSN大类名称复分大类分区是否top期刊2009年影响因子1680-7316地学1Y 4.881 0003-0007地学1Y 6.123 0930-7575地学1Y 3.917 0010-7999地学1Y 3.497 0012-821X地学1Y 4.062 0012-8252地学1Y 6.942 0016-7037地学1Y 4.385 0091-7613地学1Y 4.368 0266-1144地学1Y 4.039 0894-8755地学1Y 3.363 0022-3530地学1Y 3.738 0024-3590地学1Y 3.545 1752-0894地学1Y8.108 0883-8305地学1Y 3.644 0301-9268地学1Y 3.574 0277-3791地学1Y 4.245 8755-1209地学1Y8.021 0094-8276地学2Y 3.204 0022-4928地学2Y 2.911 0148-0227地学2Y 3.082 0022-1694地学2Y 2.433 0027-0644地学2Y 2.238 0066-4146地学天文1Y25.640 0935-4956地学天文1Y11.857 0067-0049地学天文1Y12.771 0004-637X地学天文2Y7.364 0360-0300工程技术1Y7.667 0730-0301工程技术1Y 3.619 1936-0851工程技术1Y7.493 1742-7061工程技术1Y 3.975 1359-6454工程技术1Y 3.760 0065-2156工程技术1Y 5.500 0724-6145工程技术1Y 4.165 1616-301X工程技术1Y 6.990 0935-9648工程技术1Y8.379 1523-9829工程技术1Y11.235 1531-7331工程技术1Y7.911 0570-4928工程技术1Y 3.243 0004-3702工程技术1Y 3.036 0142-9612工程技术1Y7.365 0960-8524工程技术1Y 4.253 0956-5663工程技术1Y 5.429 0734-9750工程技术1Y8.250 0006-3592工程技术1Y 3.377 1754-6834工程技术1Y 4.118 0008-6223工程技术1Y 4.5040897-4756工程技术1Y 5.368 0824-7935工程技术1Y 5.378 0738-8551工程技术1Y 3.567 1040-8398工程技术1Y 3.725 0958-1669工程技术1Y7.820 1388-2481工程技术1Y 4.243 0737-0024工程技术1Y 6.190 0733-8716工程技术1Y 3.758 1053-5888工程技术1Y 4.914 1089-778X工程技术1Y 4.589 0278-0046工程技术1Y 4.678 1045-9227工程技术1Y 2.889 0162-8828工程技术1Y 4.378 0098-5589工程技术1Y 3.750 0920-5691工程技术1Y 3.508 0360-3199工程技术1Y 3.945 1565-1339工程技术1Y 5.276 0749-6419工程技术1Y 4.791 0950-6608工程技术1Y 4.857 0021-9517工程技术1Y 5.288 0304-3894工程技术1Y 4.144 0959-9428工程技术1Y 4.795 1751-6161工程技术1Y 3.176 1741-2560工程技术1Y 3.739 0378-7753工程技术1Y 3.792 1570-8268工程技术1Y 3.412 1473-0197工程技术1Y 6.306 1022-1336工程技术1Y 4.263 0024-9297工程技术1Y 4.539 0927-796X工程技术1Y12.217 1369-7021工程技术1Y11.452 1361-8415工程技术1Y 3.093 1096-7176工程技术1Y 4.725 0276-7783工程技术1Y 4.485 1613-4125工程技术1Y 4.356 0883-7694工程技术1Y 6.330 1530-6984工程技术1Y9.991 1748-0132工程技术1Y13.237 1549-9634工程技术1Y 5.440 0957-4484工程技术1Y 3.137 1087-0156工程技术1Y29.495 1476-1122工程技术1Y29.504 1748-3387工程技术1Y26.309 1566-1199工程技术1Y 3.262 0018-9219工程技术1Y 4.878 1557-1955工程技术1Y 3.723 1558-3724工程技术1Y 5.6120960-8974工程技术1Y9.250 0360-1285工程技术1Y11.024 0079-6425工程技术1Y15.769 1062-7995工程技术1Y 4.702 0079-6727工程技术1Y 4.091 0079-6816工程技术1Y7.913 1364-0321工程技术1Y 4.842 1613-6810工程技术1Y 6.171 1744-683X工程技术1Y 4.869 0167-7799工程技术1Y 6.909 0924-2244工程技术1Y 4.051 1066-8888工程技术1Y 4.517 0001-1541工程技术2Y 1.955 0175-7598工程技术2Y 2.896 0009-2509工程技术2Y 2.136 0013-4686工程技术2Y 3.325 0308-8146工程技术2Y 3.146 0018-926X工程技术2Y 2.011 0018-9286工程技术2Y 2.556 0018-9448工程技术2Y 2.357 0018-9480工程技术2Y 2.076 1053-587X工程技术2Y 2.212 0888-5885工程技术2Y 1.758 0017-9310工程技术2Y 1.947 0002-7820工程技术2Y 1.944 0013-4651工程技术2Y 2.241 0376-7388工程技术2Y 3.203 0167-577X工程技术2Y 1.940 1359-6462工程技术2Y 2.949 0925-4005工程技术2Y 3.083 0257-8972工程技术2Y 1.793 0379-6779工程技术2Y 1.901 0040-6090工程技术2Y 1.727 0272-6963管理科学1Y 3.238 0025-1909管理科学1Y 2.227 0305-0483管理科学1Y 3.101 1059-1478管理科学1Y 2.080 0377-2217管理科学2Y 2.093 0001-4842化学1Y18.203 0108-7673化学化学－晶体1Y49.926 0002-5100化学1Y18.688 1433-7851化学1Y11.829 0066-426X化学1Y17.464 0161-4940化学1Y7.765 0009-2665化学1Y35.957 0306-0012化学1Y20.086 0010-8545化学1Y11.2251754-5692化学1Y8.500 0144-235X化学1Y 5.000 0002-7863化学1Y8.580 1389-5567化学1Y7.952 0265-0568化学1Y9.202 0079-6700化学1Y23.753 0167-5729化学1Y13.462 0165-9936化学1Y 6.546 0003-2700化学2Y 5.214 0022-3263化学2Y 4.219 1520-6106化学2Y 3.471 0743-7463化学2Y 3.898 0926-3373环境科学1Y 5.252 0003-0090环境科学1Y 4.133 1064-3389环境科学1Y7.091 1461-023X环境科学1Y10.318 0012-9615环境科学1Y 4.862 0012-9658环境科学1Y 4.411 0091-6765环境科学1Y 6.191 1462-2912环境科学1Y 4.909 0014-3820环境科学1Y 5.429 1540-9295环境科学1Y 6.922 1354-1013环境科学1Y 5.561 1466-822X环境科学1Y 5.913 1751-7362环境科学1Y 6.397 1352-2310环境科学2Y 3.139 0045-6535环境科学2Y 3.253 0013-936X环境科学2Y 4.630 0043-1354环境科学2Y 4.355 0065-2113农林科学1Y 3.800 0168-1923农林科学1Y 3.197 0261-1929农林科学1Y 1.580 1351-0754农林科学1Y 2.131 1467-2960农林科学1Y 4.489 1054-6006农林科学1Y 2.427 1050-4648农林科学1Y 2.892 1935-5130农林科学1Y 2.238 0016-7061农林科学1Y 2.461 1084-2020农林科学1Y 2.806 0021-8561农林科学1Y 2.469 0021-8812农林科学1Y 2.466 0022-0302农林科学1Y 2.463 1380-3743农林科学1Y 2.272 0960-3166农林科学1Y 2.161 0038-0717农林科学1Y 2.978 0361-5995农林科学1Y 2.179 0829-318X农林科学1Y 2.2920378-1135农林科学1Y 2.874 0928-4249农林科学1Y 3.579 0044-8486农林科学2Y 1.925 0706-652X农林科学2Y 1.951 0378-1127农林科学2Y 1.950 0003-1488农林科学2Y 1.714 0032-079X农林科学2Y 2.517 1526-5161社会科学1Y 4.000 0012-9682社会科学1Y 4.000 0304-4076社会科学2Y 1.902 0002-9297生物1Y12.303 0066-4154生物1Y29.875 1056-8700生物1Y18.955 1936-122X生物1Y19.304 1081-0706生物1Y19.571 1543-592X生物1Y8.190 0066-4170生物1Y11.271 0066-4197生物1Y13.235 1527-8204生物1Y11.568 0066-4227生物1Y12.804 0066-4286生物1Y11.212 1543-5008生物1Y23.460 0092-8674生物1Y31.152 1931-3128生物1Y13.021 1550-4131生物1Y17.350 1934-5909生物1Y23.563 1040-9238生物1Y10.216 0960-9822生物1Y10.992 0955-0674生物1Y14.153 0959-437X生物1Y8.987 1369-5266生物1Y10.333 0959-440X生物1Y9.344 1534-5807生物1Y13.363 0890-9369生物1Y12.075 1088-9051生物1Y11.342 0021-9525生物1Y9.575 1092-2172生物1Y12.585 1097-2765生物1Y14.608 1744-4292生物1Y12.125 1465-7392生物1Y19.527 1552-4450生物1Y16.058 1061-4036生物1Y34.284 1548-7091生物1Y16.874 1471-0056生物1Y27.822 1740-1526生物1Y17.644 1471-0072生物1Y42.198 1545-9985生物1Y12.2731040-4651生物1Y9.293 1544-9173生物1Y12.916 1553-7390生物1Y9.532 1553-7366生物1Y8.978 0163-7827生物1Y8.167 0033-5835生物1Y10.200 0968-0004生物1Y11.572 0962-8924生物1Y12.115 0169-5347生物1Y11.564 0168-9525生物1Y8.689 1360-1385生物1Y9.883 0099-2240生物2Y 3.686 0264-6021生物2Y 5.155 0006-3495生物2Y 4.390 0950-1991生物2Y7.194 0261-4189生物2Y8.993 0021-9193生物2Y 3.940 0021-9258生物2Y 5.328 0022-2836生物2Y 3.871 0270-7306生物2Y 6.057 0305-1048生物2Y7.479 0032-0889生物2Y 6.235 0001-5962数学1Y 2.619 0003-486X数学1Y 4.174 0090-5364数学1Y 3.185 0273-0979数学1Y 3.294 0010-3640数学1Y 2.657 1615-3375数学1Y 1.905 0020-9910数学1Y 2.794 0266-5611数学1Y 1.900 0894-0347数学1Y 3.411 0162-1459数学1Y 2.322 1369-7412数学1Y 3.473 0218-2025数学1Y 2.095 0025-5610数学1Y 2.048 0065-9266数学1Y 2.240 1540-3459数学1Y 2.198 0027-3171数学1Y 2.328 1468-1218数学1Y 2.381 0272-4332数学1Y 1.953 0036-1445数学1Y 3.391 0883-4237数学1Y 3.523 1070-5511数学1Y 3.153 0165-0114数学2Y 2.138 0377-0427数学2Y 1.292 0022-0396数学2Y 1.426 0022-247X数学2Y 1.2250362-546X数学2Y 1.487 0036-1429数学2Y 1.840 1064-8275数学2Y 1.595 0108-7673物理物理－晶体1Y49.926 0001-8732物理1Y19.632 0066-4189物理1Y9.353 0163-8998物理1Y11.964 1040-8436物理1Y 5.167 1126-6708物理1Y 6.019 1863-8880物理1Y 5.814 1433-8351物理1Y10.600 0277-7037物理1Y10.623 1749-4885物理1Y22.869 1745-2473物理1Y15.491 0370-1573物理1Y17.752 0031-9007物理1Y7.328 0079-6565物理1Y 6.742 0034-4885物理1Y11.444 0034-6861物理1Y33.145 0003-6951物理2Y 3.554 0021-9606物理2Y 3.093 1098-0121物理2Y 3.475 1550-7998物理2Y 4.922 0169-409X医学1Y11.957 0065-2776医学1Y7.725 0002-9165医学1Y 6.307 0002-9270医学1Y 6.012 0002-953X医学1Y12.522 1073-449X医学1Y10.689 1600-6135医学1Y 6.433 0003-4819医学1Y16.225 0364-5134医学1Y9.317 0003-4967医学1Y8.111 0003-4932医学1Y7.900 0732-0582医学1Y37.902 0066-4219医学1Y9.940 0147-006X医学1Y24.822 0199-9885医学1Y8.783 1553-4006医学1Y13.500 0362-1642医学1Y22.468 0066-4278医学1Y18.170 0066-4308医学1Y22.750 0163-7525医学1Y7.915 0003-990X医学1Y12.257 0003-9926医学1Y9.813 1079-5642医学1Y7.235 0004-3591医学1Y7.332。
Amsacrine_拓扑异构酶Ⅱ抑制剂_51264-14-3_Apexbio
产品名: Amsacrine 修订日期: 6/30/2016产品说明书化学性质产品名:Amsacrine Cas No.:51264-14-3 分子量:393.46 分子式:C21H19N3O3S 化学名:N-[4-(acridin-9-ylamino)-3-methoxyphenyl]methanesulfonamide SMILES:COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42 溶解性:Soluble in DMSO 储存条件:Store at -20°C 一般建议: For obtaining a higher solubility , please warm the tube at 37°Cand shake it in the ultrasonic bath for a while.Stock solution can bestored below -20°C for several months.运输条件:Evaluation sample solution : ship with blue iceAll other available size: ship with RT , or blue ice upon request生物活性靶点 :DNA Damage/DNA Repair 信号通路:Topoisomerase 产品描述:Amsacrine(Amsidine,m-AMSA)是一种拓扑异构酶Ⅱ抑制剂[1].Amsacrine 是一种抗肿瘤化疗药物,用于治疗某些淋巴瘤与急性白血病.多种癌细胞系均对Amsacrine 敏感,Amsacrine 对3种膀胱癌细胞系(HT1376\RT112和RT4)和3种睾丸癌细胞系(833K\Susa 和GH)的IC50值分别为190.2 ± 27.4 ng/ml\46.1 ± 3.9 ng/ml\22.6 ± 3.1ng/ml\11.8 ± 2.0 ng/ml\5.0 ± 0.4 ng/ml 和11.7 ± 1.5 ng/ml.据发现,与膀胱细胞系相比,睾丸癌细胞系对Amsacrine 的抑制作用更敏感[1].参考文献:[1] Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A. 1984 Mar;81(5):1361-5.产品仅用于研究，不针对患者销售，望谅解。
MetaPolyzyme DNA free 产品说明书
MAC4LDFpis Rev 04/221Product InformationMetaPolyzyme, DNA freeSuitable for Microbiome researchMAC4LDFSynonym: Multilytic Enzyme Mix Storage Temperature –20 °CProduct DescriptionMetagenomics investigates all DNA that has been isolated directly from given single samples, such as environmental samples or biological organisms.1,2Metagenomics allows for the investigation of microbes that exist in extreme environments, and which have been historically difficult to isolate, culture, andstudy.3 Metagenomics has revealed the existence of novel microbial species.4 Applications ofmetagenomics work include public health dataanalysis,5,6 discovery of novel proteins, enzymes and natural products,7,8 environmental studies,9,10 and agricultural investigations.11,12Microbes are difficult to disrupt because the cell walls may form capsules or resistant spores. DNA can be extracted by using lysing enzymes such as lyticase, chitinase, zymolase, and gluculase to induce partial spheroplast formation. Spheroplasts are subsequently lysed to release DNA.MetaPolyzyme products (Cat. Nos. MAC4L, MAC4LDF) are based on a multi-lytic enzyme mixture, originally developed by Scott Tighe, for use in microbiome and DNA extraction efficiency studies, and formulated for effective lysis of microbiome samples from extreme environments. MetaPolyzyme was originally evaluated and developed in consultation and collaboration with the Association of Biomolecular Resource Facilities (ABRF) Metagenomics and Microbiome ResearchGroup (MMRG; formerly the Metagenomics Research Group, MGRG).13-16Studies of microbial communities have beenenhanced by the use of culture-independent analytical techniques such as 16S rRNA gene sequencing and metagenomics. DNA contamination during sample preparation is a major problem of sequence-based approaches. Extraction reagents free of DNA contaminants are thus essential. MetaPolyzyme, DNA free was developed to address the need for DNA-free reagents, to minimize microbial DNA contamination from reagents. This productundergoes strict quality control testing to ensure the absence of detectable levels of contaminatingmicrobial DNA using 35 cycles PCR amplification of 16S and 18S rDNA using universal primer sets.Precautions and DisclaimerFor R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.ReagentThe enzymes in MetaPolyzyme, DNA free are:• Mutanolysin • Achromopeptidase • Lyticase • Chitinase • Lysostaphin •LysozymeAll the enzymes are individually tested for theabsence of contaminating DNA using 16S and 18S PCR amplification.Mutanolysin (from Streptomyces globisporus )Mutanolysin is a muralytic enzyme (muramidase) that cleaves the β-N -acetylmuramyl-(1→4)-N -acetylglucosamine linkage of the bacterial cell wall peptidoglycan-polysaccharide, particularly the β(1→4) bond in MurNAc-GlcNAc.17 Mutanolysin particularly acts on many Gram-positive bacteria, where the enzyme’s carboxy -terminal moietiesparticipate in the recognition and binding of unique cell wall structures.MAC4LDFpis Rev 04/22AchromopeptidaseAchromopeptidase (known also as β-lytic protease 18) has potent bacteriolytic activity on many Gram-positive aerobic bacteria 19 with high lytic activity, against bacterial strains with the A1α chemotype (such as Aerococcus viridans ), and the A3αchemotype (such as Staphylococcus epidermidis ) for cell wall peptidoglycan structures. The enzyme has been reported to have particular recognition for Gly-X sites in peptide sequences, and for Gly-Gly and ᴅ-Ala-X sites in peptidoglycans.20Lyticase (from Arthrobacter luteus )Lyticase is useful in digestion of linear glucosepolymers with β(1→3) linkages, of yeast glycan coats and for spheroplast formation, and of the cell wall of active yeast cells.Chitinase (from Streptomyces griseus )Chitinase degrades chitin by enzymatic hydrolysis to N-acetyl-D-glucosamine. Degradation occurs via two consecutive enzyme reactions: •Chitodextrinase-chitinase, apoly(1,4-β-[2-acetamido-2-deoxy-D-glucoside])-glycanohydrolase, removes chitobiose units from chitin.•N-acetylglucosaminidase-chitobiase cleaves the disaccharide to its monomer subunits, N-acetyl-D-glucosamine (NAGA).Lysostaphin (from Staphylococcus staphylolyticus )Lysostaphin is a lytic enzyme with activity against Staphylococcus species, including S. aureus . Lysostaphin has hexosaminidase, amidase, and endopeptidase activities. It cleaves polyglycine crosslinks in the cellular wall of Staphylococcus species, which leads to cell lysis.21,22Lysozyme (from chicken egg white)Lysozyme hydrolyzes β(1→4) linkages betweenN -acetylmuraminic acid and N -acetyl-D-glucosamine residues in peptidoglycan, and betweenN -acetyl-D-glucosamine residues in chitodextrin. Lysozyme lyses the peptidoglycan cell wall of Gram-positive bacteria.23Storage/StabilityThis product ships at cooler temperature conditions. Long-term storage at –20 °C is recommended. Reconstituted solutions of MetaPolyzyme, DNA free may be stored at –20 °C, but long-term solution stability has not been examined.Preparation InstructionsBecause of the great diversity of samples formetagenomics studies, it will be necessary for each researcher to work out particular conditions for optimal sample preparation and treatment. It is recommended to reconstitute MetaPolyzyme, DNA free in sterile PBS buffer, pH 7.5 (no EDTA, calcium or magnesium present in solution). The following is a sample procedure, to be scaled appropriately:1. Add 100 µL of sterile PBS (pH 7.5) to 1 vial ofMetaPolyzyme, DNA free.1.1. Resuspend by gentle agitation or pipetting. 1.2. Set solution aside at 2-8 °C until Step 7. 2. Thoroughly suspend sample in sterile PBS(pH 7.5). 3. Add 200 µL of sample in PBS to a 2 mLpolypropylene microcentrifuge tube. 4. Optional pellet wash:4.1. To sample tube, add 1 mL of PBS (pH 7.5). 4.2. Vortex, centrifuge and remove supernatant. 4.3. Repeat pellet wash two more times ifneeded. 5. Resuspend pelleted sample in 150 µL of PBS(pH 7.5). Vortex thoroughly.6. Optional: if solution will sit for more than 4 hours,sodium azide may be added to 0.02%. 7. Add 20 µL (*) of MetaPolyzyme, DNA free tosample solution. 8. Incubate at 35 °C for 2-24 hours.9. Continue with standard DNA extraction protocol. (*) The optimal volume and concentration of MetaPolyzyme, DNA free may vary in different experiments.References1. Gilbert, J.A., and Dupont, C.L., Ann. Rev. MarineSci., 3, 347-371 (2011). 2. Kang, H.S., and Brady, S.F., J. Am. Chem. Soc.,136(52), 18111-18119 (2014). 3. Ufarté, L. et al., Biotechnol. Adv., 33(8),1845-1854 (2015). 4. Davison, M. et al., Photosynth. Res., 126(1),135-146 (2015). 5. Afshinnekoo, E. et al., Cell Syst., 1(1), 72-87(2015).The life science business of Merck operatesas MilliporeSigma in the U.S. and Canada.Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.MAC4LDFpis Rev 04/22 DK,DT,GCY,TJ,RBG,SBC,MAM36.The MetaSUB International Consortium,Microbiome, 4, 24 (2016). [Erratum inMicrobiome, 4, 45 (2016).]7.Trinidade, M. et al., Front. Microbiol., 6, 890(2015).8.Coughlan, L.M. et al., Front. Microbiol., 6, 672(2015).9.Palomo, A. et al., ISME J., 10(11), 2569-2581(2016).10.Pold, G. et al., Appl. Environ. Microbiol., 82(22),6518-6530 (2016).11.Mitra, N. et al., J. Gen. Virol., 97(8), 1771-1784(2016).12.Theuns, S. et al., Infect. Genet. Evol., 43,135-145 (2016).13.Baldwin, D.A. et al., "Life at the Extreme", ABRFMetagenomics Research Group Poster 2015,presented at the ABRF 2015 Conference, St.Louis, MO, USA, March 28-31, 2015.14.Baldwin, D.A. et al., "Implementing NewStandards in Metagenomics and the ExtremeMicrobiome Project", ABRF MetagenomicsResearch Group Poster 2016, presented at theABRF 2016 Conference, Fort Lauderdale, FL, USA, February 20-23, 2016.15.McIntyre, A. et al., "Life at the Extreme: TheABRF Metagenomics Research Group", ABRFMetagenomics Research Group Poster 2017,presented at the ABRF 2017 Conference, SanDiego, CA, March 25-28, 2017.16.Tighe, S. et al., J. Biomol. Tech., 28(1), 31-39(2017).17.Gründling, A., and Schneewind, O., J. Bacteriol.,188(7), 2463-2472 (2006).18.Li, S.L. et al., J. Bacteriol., 172(11), 6506-6511(1990).19.Ezaki, T., and Suzuki, S., J. Clin. Microbiol.,16(5), 844-846 (1982). 20.Li, S. et al., J. Biochem., 124(2), 332-339(1998).21.Browder, H.P. et al., Biochem. Biophys. Res.Commun., 19, 383-389 (1965).22.Robinson, J.M. et al., J. Bacteriol., 137(3),1158-1164 (1979).23.Vocaldo, D.J. et al., Nature, 412(6849), 835-838(2001).NoticeWe provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose. The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.Technical AssistanceVisit the tech service page at/techservice.Standard WarrantyThe applicable warranty for the products listed in this publication may be found at /terms. Contact InformationFor the location of the office nearest you, go to /offices.。
FDA批准的放射性药物都有哪些？
FDA批准的放射性药物都有哪些？展开全文中华医学会核医学分会放射性药物学组整理1、药物名称：Carbon-11 choline（11C-胆碱）生产商：Mayo Clinic 商品名：—用途：前列腺癌复发诊断2、药物名称：Carbon-14 urea（14C-尿素）生产商：Kimberly-Clark 商品名：PYtest用途：胃中幽门螺杆菌感染诊断3、药物名称：Fluorine-18 florbetaben（18F-AV1）生产商：Piramal Imaging 商品名：Neuraceq™用途：阿尔茨海默（AD）患者和痴呆患者评价4、药物名称：Fluorine-18florbetapir（18F-AV45）生产商：Eli Lilly 商品名：Amyvid™用途：阿尔茨海默症诊断与治疗5、药物名称：Fluorine-18sodium fluoride（18F-氟化钠）生产商：Various 商品名：—用途：成骨能力的骨显像剂6、药物名称：Fluorine-18fludeoxyglucose（18F-FDG）生产商：Various 商品名：—用途：肿瘤、癫痫病灶糖代谢异常检测7、药物名称：Fluorine-18flutemetamol（18F-PIB）生产商：GE Healthcare 商品名：Vizamyl用途：阿尔茨海默（AD）患者和痴呆患者评价8、药物名称：Gallium-67 citrate（67Ga-柠檬酸）生产商：Lantheus MedicalImaging、Mallinckrodt商品名：—用途：霍奇金病、淋巴瘤、支气管癌以及一些急性炎症病变诊断9、药物名称：Indium-111capromab pendetide（111In-卡罗单抗喷地肽）生产商：AytuPharmaceuticals 商品名：ProstaScint®用途：前列腺癌患者、前列腺癌术后高度怀疑转移患者的检测10、药物名称：Indium-111 chloride（111In-氯化铟）生产商：GE Healthcare、Mallinckrodt 商品名：Indiclor™用途：用于放射性标记11、药物名称：Indium-111 pentetate（111In-DTPA）生产商：GE Healthcare 商品名：—用途：放射性核素脑池造影12、药物名称：Indium-111oxyquinoline（111In-羟基喹啉）生产商：GE Healthcare 商品名：—用途：用于自体白细胞标记，炎症及感染的诊断13、药物名称：Indium-111pentetreotide（111In-奥曲肽）生产商：Mallinckrodt 商品名：Octreoscan™用途：原发性和转移性内神经分泌肿瘤生长抑素受体定位14、药物名称：Iodine I-123iobenguane（123I-MIBG）生产商：GE Healthcare 商品名：AdreView™用途：原发或转移性嗜铬细胞瘤或神经母细胞瘤的辅助诊断15、药物名称：Iodine I-123 ioflupane（123I-氟潘）生产商：GE Healthcare 商品名：DaTscan™用途：对疑似帕金森症患者的评估16、药物名称：Iodine I-123sodium iodide capsules（123I-碘化钠胶囊）生产商：Cardinal Health、Mallinckrodt 商品名：—用途：甲状腺功能及形态学评价17、药物名称：Iodine I-125 humanserum albumin（125I-人血清白蛋白）生产商：IsoTex Diagnostics 商品名：Jeanatope用途：全血及血浆容量测定18、药物名称：Iodine I-125iothalamate（125I-酞酸盐）生产商：IsoT ex Diagnostics商品名：Glofil-125用途：肾小球滤过率的评价19、药物名称：Iodine I-131 humanserum albumin（131I-人血清白蛋白）生产商：IsoTex Diagnostics 商品名：Megatope用途：全血及血浆量、心脏输出、心脏及肺血容量、蛋白质周转研究、脑肿瘤定位等20、药物名称：Iodine I-131sodium iodide（131I-碘化钠）生产商：DRAXIMAGE、Mallinckrodt 商品名：HICON™用途：甲状腺疾病的诊断与治疗21、药物名称：MolybdenumMo-99 generator（钼锝发生器）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：DRYTEC™、T echnelite、UltraTechneKow®DTE用途：放射性药物的制备22、药物名称：Nitrogen-13 ammonia（13N-氨水）生产商：Various 商品名：—用途：心肌灌注评价冠状动脉疾病23、药物名称：Radium-223 dichloride（223Ra-二氯化镭）生产商：Bayer HealthCarePharmaceuticalsInc. 商品名：Xofigo®用途：去势性前列腺癌治疗24、药物名称：Rubidium-82 chloride（82Ru-氯化铷）生产商：Bracco Diagnostics 商品名：Cardiogen-82®用途：心肌灌注显像剂25、药物名称：Samarium-153lexidronam（153Sm-EDTMP）生产商：Lantheus MedicalImaging 商品名：Quadramet®用途：减轻骨转移患者的疼痛26、药物名称：Strontium-89 chloride（89Sr-氯化锶）生产商：GE Healthcare商品名：MetastronTM用途：减轻骨转移患者的疼痛27、药物名称：T echnetium-99mbicisate（99mT c-ECD）生产商：Lantheus MedicalImaging 商品名：Neurolite®用途：脑卒中患者卒中的诊断与治疗28、药物名称：Technetium-99mdisofenin（99mTc-地索芬宁）生产商：Pharmalucence 商品名：Hepatolite®用途：急性胆囊炎诊断29、药物名称：Technetium-99mexametazine（99mTc-HMPAO）生产商：GE Healthcare 商品名：C eretec™用途：脑卒中患者血脑灌注、白细胞标记显像用用于腹腔感染及肠道炎症定位30、药物名称：T echnetium-99mmacroaggregatedalbumin （99mT c-MAA）生产商：DRAXIMAGE 商品名：—用途：肺灌注评价、腹静脉分流畅通性评价31、药物名称：Technetium-99mmebrofenin（99mT c-甲溴苯宁）生产商：Bracco Diagnostics、Pharmalucence 商品名：Choletec®用途：肝胆显像剂32、药物名称：Technetium-99mmedronate（99mTc-MDP）生产商：DRAXIMAGE、GE Healthcare、Pharmalucence 商品名：MDP-25、MDP Multidose用途：骨显像剂33、药物名称：Technetium-99mmertiatide（99mTc-MAG3）生产商：Mallinckrodt 商品名：TechnescanMAG3TM用途：肾动态显像34、药物名称：Technetium-99moxidronate（99mT c-HDP）生产商：Mallinckrodt 商品名：Tec hnescan™HDP用途：骨显像剂35、药物名称：Technetium-99mpentetate（99mT c-DTPA）生产商：DRAXIMAGE 商品名：—用途：脑显像、肾显像36、药物名称：T echnetium-99mpyrophosphate（99mTc-PYP）生产商：Mallinckrodt、Pharmalucence 商品名：Technescan™、PYP™用途：骨显像、心脏显像剂、血池显像剂37、药物名称：Technetium-99m redblood cells（99mT c-红细胞）生产商：Mallinckrodt 商品名：UltraTag™用途：血池造影、消化道出血定位38、药物名称：T echnetium-99msestamibi（99mTc-MIBI）生产商：Cardinal Health、DRAXIMAGE、Lantheus MedicalImaging、Mallinckrodt、Pharmalucence商品名：Cardiolite®用途：心肌灌注，用于检测缺血、评价心机功能，乳腺成像39、药物名称：Technetium-99msodium pertechnetate （99mT c-高锝酸钠）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：—用途：脑显像、甲状腺显像、胎盘定位、膀胱显像等40、药物名称：Technetium-99msuccimer（99mT c-DMSA）生产商：GE Healthcare 商品名：—用途：肾显像41、药物名称：Technetium-99msulfur colloid（99mT c-硫胶体）生产商：Pharmalucence 商品名：—用途：肝、脾、骨髓显像等42、药物名称：Technetium-99mtetrofosmin（99mTc-替曲膦）生产商：GE Healthcare 商品名：MyoviewTM用途：心肌灌注剂43、药物名称：Technetium-99mtilmanocept（99mTc-替马诺噻）生产商：NavideaBiopharmaceuticals,Inc. 商品名：Lymphoseek®用途：淋巴结定位44、药物名称：Thallium-201chloride（201Tl-氯化铊）生产商：GE Healthcare、Lantheus MedicalImaging、Mallinckrodt商品名：—用途：心肌灌注显像45、药物名称：Xenon-133 gas（133Xe气体）生产商：Lantheus MedicalImaging 商品名：—用途：肺功能评估与肺显像、脑血流评估46、药物名称：Yttrium-90chloride（90Y-氯化钇）生产商：MDS Nordion、Eckert＆ZieglerNuclitec商品名：—用途：放射性标记47、药物名称：Yttrium-90ibritumomab tiuxetan（90Y-替伊莫单抗）生产商：SpectrumPharmaceuticals商品名：Zevalin®用途：非霍奇金氏淋巴瘤治疗截止至2015年8月1日。
Amsacrine_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :AmsacrineCatalog No. :HY-13551CAS No. :51264-14-31.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:AMSA; m⁻AMSA; CI⁻880; SN⁻11841; acridinyl anisidideFormula:C21H19N3O3SMolecular Weight:393.46CAS No. :51264-14-34. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Pink to red (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
碧云天生物技术 3M NaAc pH5.2 (Sterile, DNase free)说明书
碧云天生物技术/Beyotime Biotechnology订货热线：400-168-3301或800-8283301订货e-mail：******************技术咨询：*****************碧云天网站微信公众号网址：3M NaAc, pH5.2 (Sterile, DNase free)产品编号产品名称包装ST351 3M NaAc, pH5.2 (Sterile, DNase free) 100ml产品简介：3M NaAc pH5.2 (Sterile, DNase free)，即无菌，无DNA酶污染的醋酸钠缓冲液，是一种常用的分子生物学试剂。
本产品无菌，无DNA酶污染，主要用于DNA的乙醇沉淀等。
NaAc即醋酸钠(Sodium Acetate)，也称乙酸钠，分子式为CH3COONa，分子量82.03，CAS号127-09-3。
DNA是一种多聚阴离子水溶性化合物，在DNA提取过程中，经常需要加入醋酸钠等适当的缓冲液并用乙醇等适当有机溶剂来沉淀DNA。
其原理是乙醇能夺取DNA周围的水分子，使DNA失水从而易于聚合；同时乙醇也能够消除DNA的水化层使带负电荷的磷酸基团暴露出来与醋酸钠缓冲液中的高浓度钠离子(Na+)结合，从而减少DNA分子之间的同性电荷排斥力而更易于聚合，最终形成DNA钠盐沉淀。
在低温环境下，这种促沉淀效应会被加强，因此对于低浓度DNA或者较难沉淀的小分子量DNA通常宜在-20ºC或-70ºC等低温条件下沉淀，以提高沉淀效率。
本产品常用于各种常见DNA样品的浓缩和纯化。
包装清单：产品编号产品名称包装ST351 3M NaAc, pH5.2 (Sterile, DNase free) 100ml—说明书1份保存条件：室温保存。
注意事项：本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
Agilent GeneJammer 转染试剂,货号 204131 - 化学品安全说明书
GeneJammer Transfection Reagent, Part Number 204131*************(24小时)化学品安全技术说明书GHS product identifier 应急咨询电话（带值班时间）::供应商/ 制造商:安捷伦科技贸易（上海）有限公司中国（上海）外高桥自由贸易试验区英伦路412号（邮编:200131)电话号码： 800-820-3278传真号码: 0086 (21) 5048 2818GeneJammer Transfection Reagent, Part Number 204131化学品的推荐用途和限制用途204131部件号:安全技术说明书根据 GB/ T 16483-2008 和 GB/ T 17519-2013GHS化学品标识:GeneJammer 转染试剂，货号 204131推荐用途:有关环境保护措施，请参阅第 12 节。
物质或混合物的分类根据 GB13690-2009 和 GB30000-2013紧急情况概述液体。
无资料。
无资料。
物理状态:颜色:气味:GHS危险性类别警示词:危险危险性说明::防范说明预防措施:P241 - 使用防爆的电气、通风、照明设备。
P242 - 使用不产生火花的工具。
P243 - 采取行动防止静电放电。
P233 - 保持容器密闭。
P264 - 作业后彻底清洗。
标签要素象形图易燃液体 - 类别 2严重眼损伤/眼刺激 - 类别 2AP305 + P351 + P338 - 如进入眼睛： 用水小心冲洗几分钟。
如戴隐形眼镜并可方便地取出，取出隐形眼镜。
继续冲洗。
P337 + P313 - 如仍觉眼刺激： 求医要么就诊。
安全储存:废弃处置:P501 - 处置内装物/容器按照地方/区域/国家/国际规章。
物理和化学危险高度易燃液体和蒸气。
健康危害::与物理,化学和毒理特性有关的症状皮肤接触食入吸入没有具体数据。
没有具体数据。
代谢检测试剂盒指南
检测法 带有近红外荧光读数、比色或荧光读数的In-Cell ELISA 蛋白质印迹抗体混合（Cocktail） ICC 抗体混合（Cocktail） 流式抗体混合（Cocktail）
检测试剂盒 ab110217, ab110216, ab140359
ab123545 ab170194 ab168540
JC-1：ab113850
酶标仪、显微镜、590/520-570) 在高浓度下形成红色聚集物（未聚 JC-10 （比
检测法
读数
细胞外耗氧量
细胞内氧水平 糖酵解活性（细 胞外酸化）
备注
检测试剂盒
随着细胞呼吸，氧气浓度降低，染料信号将增强。油层 ab197243
将细胞与空气隔离。
染料扩散到细胞中。染料荧光被胞内氧淬灭。
ab197245
糖酵解过程中产生乳酸，导致胞外基质酸化。染料荧光 ab197244
随酸化而增加。
脂肪酸氧化 (FAO) 乳酸
图 4.使用 In-Cell ELISA 试剂盒 ab110217 评估 COX-1（线粒体 DNA 编码） 和 SDH-A（细胞核 DNA 编码）的相对量，进而评估氯霉素对线粒体生物合 成的抑制作用。
“我正在使用该试剂盒 [ab110217] 进行 500 多种化合物的高通量筛查。该试剂盒具有很高的可重现性，而且我没有观 察到任何批间差异。强烈推荐该试剂盒。” - Analeeb Sajid 博士
abcam
工具指南
代谢 检测试剂盒指南
用于酶标仪、显微镜和流式细胞仪的简 易、精细检测试剂盒
代谢是一个复杂的过程，也是生物学的核心。代谢异常会引发从癌症到神经退行性病变等一系列 后果。 我们的简易检测试剂盒可以简化您代谢方面的研究。使用酶标仪、显微镜或流式细胞仪上的读数 来分析活细胞、裂解液和生物体液。 检查： - 糖、脂、氨基酸、糖酵解和柠檬酸循环过程中的酶等 - 耗氧量、乳酸产生以及 ATP、NADH 和类似分子 - 线粒体与线粒体功能 - 氧化应激、ROS、抗氧化剂和相关细胞损伤
超高效液相色谱-串联质谱法测定化妆品中15种N-亚硝胺化合物
第42 卷第 11 期2023 年11 月Vol.42 No.111469~1478分析测试学报FENXI CESHI XUEBAO（Journal of Instrumental Analysis）超高效液相色谱-串联质谱法测定化妆品中15种N-亚硝胺化合物汪毅1，梁文耀1，何国山1，陈张好2，周智明2，吴谦1，席绍峰1，谭建华1*（1．广州质量监督检测研究院，国家化妆品质量检验检测中心（广州），广东广州511447；2．广东省药品检验所，广东广州510663）摘要：采用超高效液相色谱-串联质谱（UPLC-MS/MS）建立了化妆品中15种痕量N-亚硝胺化合物的分析方法。
水剂样品以水或乙腈分组超声提取，膏霜乳液样品采用亚铁氰化钾-乙酸锌溶液沉淀大分子或者饱和氯化钠-乙腈盐析分组处理后，以Agilent Poroshell 120 SB-Aq（100 mm×3.0 mm，2.7 μm）色谱柱分离，经大气压化学电离源（APCI）电离，多反应监测模式检测，以同位素内标法定量。
结果表明，15种N-亚硝胺化合物在相应质量浓度范围内线性关系良好（r2＞0.995），检出限和定量下限分别为5~15 ng/g和15~45 ng/g。
水、乳、膏霜3种化妆品基质在25、50、100 ng/g加标水平下的平均回收率为88.0%~111%，相对标准偏差（RSD，n=6）为1.4%~9.8%。
该方法用于市售化妆品检测，发现13批次样品检出N-亚硝基二乙醇胺（NDELA），其中1批次超限量值。
方法的专属性强，灵敏度高，精密度好，解决了N-亚硝胺化合物稳定性差、易被干扰等问题，适用于化妆品中15种N-亚硝胺化合物的痕量测定。
关键词：N-亚硝胺化合物；化妆品；超高效液相色谱-串联质谱法（UPLC-MS/MS）；大气压化学电离源中图分类号：O657.63；O623.732文献标识码：A 文章编号：1004-4957（2023）11-1469-10 Determination of Fifteen N-nitrosamine Compounds in Cosmetics by Ultra Performance Liquid Chromatography-TandemMass SpectrometryWANG Yi1，LIANG Wen-yao1，HE Guo-shan1，CHEN Zhang-hao2，ZHOU Zhi-ming2，WU Qian1，XI Shao-feng1，TAN Jian-hua1*（1．Guangzhou Quality Supervision and Testing Institute，National Quality Supervision and Testing Center for Cosmetics（Guangzhou），Guangzhou 511447，China；2．Guangdong Institute for Drug Control，Guangzhou 510663）Abstract：An ultra performance liquid chromatography-tandem mass spectrometric（UPLC-MS/MS）method was established for detecting 15 trace N-nitrosamine compounds in cosmetics. The final estab⁃lished method involved ultrasonic extraction of cosmetics using water or acetonitrile for different com⁃pounds. The samples were treated with potassium ferrocyanide-zinc acetate solution for precipitating macromolecules or saturated sodium chloride-acetonitrile for salting out.An Agilent Poroshell 120 SB-Aq（100 mm × 3.0 mm，2.7 μm） chromatography column was used for separation，followed by atmospheric pressure chemical ionization（APCI） source and multiple reaction monitoring mode detec⁃tion in the isotope internal standard method for quantification. The result showed good linearity（r2> 0.995） for the 15 N-nitrosamine compounds in their respective concentration ranges，with detection and quantitation limits of 5-15 ng/g and 15-45 ng/g，respectively.The average recoveries for the three cosmetic matrices（aqueous，emulsion，cream） at spiked levels of 25，50，100 ng/g were be⁃tween 88.0% and 111%，with relative standard deviations（RSD，n=6） of 1.4%-9.8%. The method was applied to the detection of commercial cosmetics and N-nitrosodiethanolamine（NDELA） was de⁃tected in 13 batches，with one batch exceeding the limit. The strong specificity，high sensitivity，and good precision made the method could solve the problems of poor stability and easy interference ofdoi：10.19969/j.fxcsxb.23051602收稿日期：2023－05－16；修回日期：2023－06－10基金项目：广东省药品监督管理局化妆品风险评估重点实验室专项（2021ZDZ03）；广东省市场监督管理局科技项目（2022CZ06）∗通讯作者：谭建华，博士，正高级工程师，研究方向：色谱－质谱检测技术研究，E-mail：tanjianhua0734@第 42 卷分析测试学报N-nitrosamine compounds，and was suitable for the trace determination of 15 N-nitrosamine com⁃pounds in cosmetics.Key words：N-nitrosamine compounds；cosmetics；ultra performance liquid chromatography-tan⁃dem mass spectrometry（UPLC-MS/MS）；atmospheric pressure chemical ionization（APCI） sourceN-亚硝胺化合物是一类具有N-亚硝基结构的化合物，因取代基的不同，形成了种类繁多的同系物，目前已发现超过300种［1］。
Ia医药生化试剂
浓度
纯度
型号
规格
500ml/瓶 5g/瓶
单位
瓶 瓶 瓶 瓶 瓶 支 支 瓶 瓶 瓶 瓶 瓶 箱 瓶 合 瓶 瓶 瓶 甁 瓶 支 支 瓶 支 瓶 瓶 瓶 支 克拉玛尔 Sigma
品牌/厂家
科伦制药有限公司
解剖
组胚
分析纯 生化试剂 生化试剂 生化试剂 生化试剂 60~80目 分析纯 分析纯 医用 进口分装 进口分装
北京义翘神舟生物
Ia101
北京义翘神舟生物
Ia102
北京义翘神舟生物
Ia103 Ia104 Ia105 Ia106 Ia107 Ia108 Ia109 Ia110 Ia111 Ia112 Ia113 Ia114 Ia115 Ia116 Ia117 Ia118 Ia119 Ia120 Ia121 Ia122
浓度
纯度
型号
规格
100克/瓶
单位
瓶 瓶 瓶 支 瓶 瓶 瓶 瓶
品牌/厂家
whatman分装 北京索莱宝科技有限公司 上海原叶 福州迈新生物技术开发有限公 司 吉诺生物医药 西陇化工股份有限公司 国药集团化学试剂有限公司 赛齐（上海）生物工程有限公 司 GIBCO 汕头市西陇化工厂有限公司 北京艾德莱生物科技有限公司 上海生工 天根生化科技有限公司 厂家：上海生工 天根生化科技有限公司 索莱宝 福州迈新生物技术开发有限公 司 厂家：上海生工 NEB 上海生工 中天美行 天津光复 汕头市西陇化工厂有限公司 福州迈新生物技术开发有限公 司 北京索莱宝科技有限公司 NEB公司
浓度
纯度
分析纯 AR 分析纯 AR 分析纯 分析纯 生化试剂 化学纯
型号
规格
10ml/支 100ml/瓶 250ml/瓶 25毫升/瓶 100ml/瓶 100毫升/瓶 100毫升/瓶
染色及助剂环保标准--2009年要求
邻氨基偶氮甲苯
97-56-3
４氨基联苯
92-67-1
５硝基邻甲苯胺
99-55-8
邻氨基苯甲醚
90-04-0
联苯胺
92-87-5
对氯苯胺
106-47-8
４氯邻甲苯胺
95-69-2
２甲氧基５甲基苯胺
120-71-8
２，４二氨基苯甲醚
615-05-4
４，４二氨基二苯甲烷
2682-20-4
五氯化苯酚(PCP)
87-86-5
未检出
§64 LFGB B 82.02.8(RL=0.5)
四氯苯酚(TeCP)
25167-83-3
富马酸二甲酯
624-49-7
禁止使用
溶剂萃取/GC-MS
IV) Bisphenol-A (BPA)双酚A
化学物质
CAS编号
产品最高限量
(ppm)
检检法
4,4dihydroxy2,2diphenylpropane
80-05-7
未检出
GC-MS/
LC-MS
V)抗光敏性致癌的分散染料及其它染料
化学物质
CAS编号
产品最高限量
检测法
(ppm)
分散染料
未检出
DIN54231单位：
毫克/升（RL：5）
分散蓝1
2475-45-8
分散蓝3
2475-46-9
分散蓝7
4098-71-9
游离型:1
封闭型: 100
四甲基苯二甲基二异氰酸酯
(TMXDI)
2778-42-9
游离型:1
封闭型: 100
甲苯异氰酸酯
(TDI)
用于肿瘤靶向性X线CT造影剂和抗肿瘤药物传递的多功能含碘纳米粒子的制备和表征
用于肿瘤靶向性X线CT造影剂和抗肿瘤药物传递的多功能含碘纳米粒子的制备和表征朱颖;张岩;陈研;杨晓英【摘要】目的:制备用于肿瘤靶向性X线CT造影剂和抗肿瘤药物传递的多功能含碘纳米粒子,用于肿瘤诊断和治疗.方法:利用沉淀聚合法制备含碘聚合物纳米粒子P(MATIB-co-MBA-co-GMA)-FA-AuNP,该纳米粒子以2-甲基丙烯酰(3-酰胺-2,4,6-三碘苯甲酸)(MATIB)为单体,以N,N’-亚甲基双丙烯酰胺为交联剂(MBA),通过甲基丙烯酸缩水甘油酯(GMA)和乙二胺(EDA)将叶酸分子修饰到该纳米粒子表面,并原位沉积金纳米粒子(AuNP).结果:TEM结果显示该纳米粒子分散均匀,平均粒径为135 nm.体外X线CT成像检测结果表明AuNP的掺杂显著增加了该纳米粒子的X线衰减性能.该纳米粒子同时可高效负载抗肿瘤药物(DOX),载药量为51.3％,并具有pH敏感的可控释放性能.体外药物输送结果显示有FA修饰的纳米粒子能更好地携载抗肿瘤药物进入肿瘤细胞.细胞毒性的结果显示该P(MATIB-co-MBA-co-GMA)-FA-AuNP纳米粒子在浓度低于100 μg/mL时未显示明显毒性.载药后,有叶酸修饰的纳米粒子对肿瘤细胞具有更好的杀伤性能.结论:该纳米粒子可同时作为肿瘤靶向性X线CT造影剂和抗肿瘤药物载体,用于肿瘤诊断和治疗.【期刊名称】《天津医科大学学报》【年(卷),期】2018(024)002【总页数】9页(P122-130)【关键词】沉淀聚合;肿瘤靶向;CT造影剂;药物输送【作者】朱颖;张岩;陈研;杨晓英【作者单位】天津医科大学药学院,天津市临床药物关键技术重点实验室,天津300070;天津医科大学第二医院药学部,天津300211;天津医科大学药学院,天津市临床药物关键技术重点实验室,天津300070;天津医科大学药学院,天津市临床药物关键技术重点实验室,天津300070;天津医科大学药学院,天津市临床药物关键技术重点实验室,天津300070【正文语种】中文【中图分类】O63计算机断层扫描（CT）是目前临床上应用最广泛的非侵入性成像诊断技术之一，在临床已经使用大半个世纪。
IFCC Aspartate Aminotransferase 检测手册说明书
ASTAspartate Aminotransferase IFCCMANUAL RX MONZAINTENDED USEFor the quantitative in vitro determination of AspartateAminotransferase (AST) in serum and plasma. This product is suitable for manual use and on the Rx Monza analyser.Cat. No. AS 1202 R1a. Buffer/Substrate 1 x 70 ml 20 x 2 ml R1b. Enzyme/Coenzyme/ 20 x 2 ml α-oxoglutarate GTIN: 05055273200416AS 1204 R1a. Buffer/Substrate 1 x 105 ml 10 x 10 ml R1b. Enzyme/Coenzyme/ 10 x 10 ml α-oxoglutarate GTIN: 05055273200423AS 1267 R1a. Buffer/Substrate 1 x 105 ml 5 x 20 ml R1b. Enzyme/Coenzyme/ 5 x 20 ml α-oxoglutarate GTIN: 05055273200430AS 2359 R1a. Buffer/Substrate 5 x 100 ml 5 x 100 ml R1b. Enzyme/Coenzyme/ 5 x 100 ml α-oxoglutarate GTIN: 05055273200454UV METHODThis is an optimised standard method according to the concentrations recommended by the IFCC.CLINICAL SIGNIFICANCE (1,2,3,4)The aminotransferases are a group of enzymes that catalyse the inter conversions of amino acids and α-oxoacids by transfer of amino groups. AST (aspartate aminotransferase or glutamate oxaloacetatetransaminase) has been found in the cytoplasm and the mitochondria of cells that have been studied. In cases of mild tissue damage, e.g. liver, the predominant form of serum AST is that from the cytoplasm, with a smaller amount coming from the mitochondria. Severe tissue damage will result in more mitochondrial enzyme being released. Elevated levels of AST can signal myocardial infarction, hepatic disease, muscular dystrophy and organ damage.Although heart muscle is found to have the most activity of the enzyme, significant activity has also been seen in the brain, liver, gastric mucosa, adipose tissue and kidneys of humans.The IFCC has now recommended (1980) standardised procedures for AST determinations including:-1. optimization of substrate concentrations.2. Employment of Tris buffers (instead of phosphate, which has beenshown to inhibit recombination of the apoenzyme with pyridoxal phosphate).3. Pre-incubation of combined buffer and serum to allow sidereactions with NADH to occur. 4. Substrate start (α-oxoglutarate)5. Optional pyridoxal phosphate activation.This is an optimised standard method according to the recommendations of the IFCC.PRINCIPLEα-oxoglutarate reacts with L-aspartate in the presence of AST to form L-glutamate plus oxaloacetate. The indicator reaction utilises the oxaloacetate for a kinetic determination of NADH consumption. AST -oxoglutarate + L-aspartate L-glutamate + oxaloacetate MDH oxaloacetate + NADH + H + L-malate + NAD +SPECIMEN COLLECTION AND PREPARATION (5) Serum:- Use serum free from haemolysis.Plasma:- EDTA or heparin can be used as the anticoagulant.Plasma should be separated from cells within one hour after collection.Specimens should be refrigerated if not used immediately:-Specimens stored longer than 3 days should be frozen at -20︒C.REAGENT COMPOSITIONContents Concentrations in the TestR1a. Buffer/Substrate Tris buffer 80 mmol/l, pH 7.5 L-aspartate 240 mmol/l R1b. Enzyme/Coenzyme/α-oxoglutarate α-oxoglutarate 12 mmol/l MDH ≥420 U/l LD ≥600 U/l NADH 0.18 mmol/lSAFETY PRECAUTIONS AND WARNINGS For in vitro diagnostic use only. Do not pipette by mouth.Exercise the normal precautions required for handling laboratory reagents.Solution R1a contains Sodium Azide. Avoid ingestion or contact with skin or mucous membranes. In case of skin contact, flush affected area with copious amounts of water. In case of contact with eyes or if ingested, seek immediate medical attention.Sodium Azide reacts with lead and copper plumbing, to form potentially explosive azides. When disposing of such reagents flush with large volumes of water to prevent azide build up. Exposed metal surfaces should be cleaned with 10% sodium hydroxide.Health and Safety data sheets available on request.The reagents must be used only for the purpose intended by suitably qualified laboratory personnel, under appropriate laboratory conditions.STABILITY AND PREPARATION OF REAGENTS R1a. Buffer/SubstrateContents ready for use. Stable up to the expiry date when stored at +2 to +8︒C.R1b. Enzyme/Coenzyme/α-oxoglutarate Reconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with the appropriate volume of Buffer/Substrate R1a: 2 ml for the 20 x 2 ml kit (AS 1202) 10 ml for the 10 x 10 ml kit (AS 1204) 20 ml for the 5 x 20 ml kit (AS 1267) Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C. Cat. AS 2359 5 x 100 mlReconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with a portion of Buffer/Substrate R1a and then transfer the entire contents to bottle R1a rinsing bottle R1b several times. Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C.MATERIALS PROVIDED Buffer/SubstrateEnzyme/Coenzyme/ -oxoglutarateMATERIALS REQUIRED BUT NOT PROVIDEDRandox Assayed Multisera Level 2 (Cat. No. HN 1530) and Level 3 (Cat. No. HE 1532)Randox Calibration Serum Level 3 (Cat. No. CAL 2351) RX series Saline (Cat. No. SA 3854)PROCEDUREAspirate fresh ddH 2O and perform a new Gain Calibration in flow cell mode. Select AST in the Run Test screen and carry out a water blank as instructed.Pipette into a test tube:Sample 0.05 ml Reagent 0.5 mlMix and aspirate into the Rx Monza.CALIBRATION FOR RX MONZAThe use of Saline and Randox Calibration Serum Level 3 isrecommended for calibration. Calibration is recommended with change of reagent lot or as indicated by quality control procedures.FOR MANUAL USEWavelength: 340 nm (Hg 334 nm or Hg 365 nm) Cuvette: 1 cm light path Temperature: 25/30/37︒C Measurement: against airPipette into cuvette: Macro MicroSample 0.2 ml 0.1 ml Enzyme/Coenzyme/ α-oxoglutarate R1 2.0 ml 1.0 mlMix, read initial absorbance after 1 minute. Read again after 1, 2 and 3 minutes. Note: If the absorbance change per minute is between 0.11 and 0.16 at 340/Hg 334 nm 0.06 and 0.08 at Hg 365 nmuse only the values for the first 2 minutes for the calculation.MANUAL CALCULATIONTo calculate the AST activity, use the following formulae:U/l = 1746 x A 340 nm/min U/l = 1780 x A Hg 334 nm/min U/l = 3235 x A Hg 365 nm/minSTANDARDISATIONRandox Calibration Serum Level 3 is traceable to AST reference material JSCC TS01.QUALITY CONTROLRandox Assayed Multisera, Level 2 and Level 3 are recommended for daily quality control. Two levels of controls should be assayed at least once a day. Values obtained should fall within a specified range. If these values fall outside the range and repetition excludes error the following steps should be taken:1. Check instrument settings and light source.2. Check cleanliness of all equipment in use.3. Check water. Contaminants, i.e. bacterial growth, maycontribute to inaccurate results. 4. Check reaction temperature.5. Check expiry date of kit and contents.6. Contact Randox Laboratories Customer Technical Services, Northern Ireland +44 (0) 28 9445 1070.SPECIFICITY/INTERFERENCE (6,7)Gross haemolysis will produce falsely elevated test results. The effects of various drugs on AST activity should be taken intoconsideration in the case of patients receiving large doses of drugs.The analytes below were tested up to the following levels and were found not to interfere: Haemoglobin 250 mg/dl Free Bilirubin 25 mg/dl Conjugate Bilirubin 25 mg/dl Triglycerides 1000 mg/dlIntralipid ® 200 mg/dlA list of substances and conditions known to effect AST activity in vivo is given by both Young et al and Friedman et al. Norepresentation is made by Randox Laboratories Ltd regarding the completeness of these lists and the accuracy of the information contained therein.NORMAL VALUES IN SERUM (8,9) +25︒C +30︒C +37︒C Men up to 18 U/l up to 25 U/l up to 37 U/l Women up to 15 U/l up to 21 U/l up to 31 U/lIt is recommended that each laboratory establish its own reference range to reflect the age, sex, diet and geographical location of the population.SPECIFIC PERFORMANCE CHARACTERISTICS The following performance data were obtained using an Rx Monza analyser running at +37o C.LINEARITYThis method is linear up to 562 U/l. If the sample concentration exceeds this value, dilute the sample 1+9 with 0.9% NaCl solution and re-assay. Multiply the result by 10.SENSITIVITYThe minimum detectable concentration of AST with an acceptable level of precision was determined as 9.3 U/l.PRECISIONIntra AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.66 1.47CV(%) 4.65 0.96n 20 20Inter AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.77 7.10CV(%) 4.96 4.63n 20 20CORRELATIONThis method (Y) was compared with another commerciallyavailable method (X) and the following linear regression equationobtained:Y = 1.07X + 4.9and a correlation coefficient of r = 0.997543 patient samples were analysed spanning the range 28 to 559U/l.REFERENCES1. Wroblewski F, La Due J.S: Ann Intern Med. 1956; 45: 801.2. Wroblewski F, La Due J.S: Proc Soc Exp Biol Med 1956;91: 569.3. Bergmeyer HU, Bowers GN Jr, et al: Clin Chem 1977; 23:887.4. Bergmeyer HU, Bowers GN Jr, et al: J.Clin Chem ClinBiochem 1980; 18: 521-534.5. Tietz N W: Fundamentals of Clinical Chemistry ed 3.Philadelphia, WB Saunders Co. 1987, pg 372.6. Young D S, et al: Clin Chem 1975, 21; No5.7. Friedman RB, et al: Clin Chem 1980, 26; No4.8. Wallnofer H, Schmidt.E, Schmidt FW, eds: Synopsis derLeberkrankheiten Stuttgart, Georg Thieme Verlag, 1974.9. Thefeld W, et al: Dtsch Med Wschr 1974; 99: 343.Revised 26 Apr 16 biRev. 003THIS PAGE IS INTENTIONALLY BLANK。
Y-27632_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Y–27632 is an ATP–competitive inhibitor of ROCK–I and ROCK–II , with K i of 220 nM and 300 nM for ROCK–I and ROCK–II , respectively.IC50 & Target: Ki: 220/300 nM (ROCK–I/II)[1]In Vitro: Y–27632 inhibits the ROCK family of kinases 100 times more potently than other kinases including protein kinase C,cAMP–dependent kinase and myosin light chain kinase. Y–27632 prolongs the lag time and delays the appearance of BrdU–labeled cells in a concentration–dependent manner, delays of about 1 and 4 h are noticed in the Swiss 3T3 cells treated with 10 and 100 μM Y–27632, respectively [1]. Y–27632 promotes neuronal differentiation of adipose tissue–derived stem cells (ADSCs). Compared to 1.0and 2.5 μM Y–27632 induced groups, percentages of neuroal–like cells achieved a peak in the 5.0 μM Y–27632 induced group [2].In Vivo: Y–27632 (5 and 10 mg/kg) significantly prolongs the onset time of myoclonic jerks when compare with saline group.Y–27632 (5 and 10 mg/kg) significantly prolongs the onset time of clonic convulsions when compare with saline group [3].Treatment with Dimethylnitrosamine (DMN) causes a significant decrease in rat body and liver weight (DMN–S group) compared with control animals (S–S group). Oral Y27632 (30 mg/kg) essentially prevents this DMN–induced rat body and liver weight loss (DMN–Y group)[4].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Recombinant ROCK–I, ROCK–II, PKN, or citron kinase is expressed in HeLa cells as Myc–tagged proteins by transfection using Lipofectamine, and is precipitated from the cell lysates by the use of 9E10 monoclonal anti–Myc antibodycoupled to G protein–Sepharose. Recovered immunocomplexes are incubated with various concentrations of [32P]ATP and 10 mg of histone type 2 as substrates in the absence or presence of various concentrations of either Y–27632 or Y–30141 at 30°C for 30 min in a total volume of 30 μL of the kinase buffer containing 50 mM HEPES–NaOH, pH 7.4, 10 mM MgCl 2, 5 mM MnCl 2, 0.02% Briji 35, and 2 mM dithiothreitol. PKCa is incubated with 5 μM [32P]ATP and 200 μg/mL histone type 2 as substrates in the absence or presence of various concentrations of either Y–27632 or Y–30141 at 30°C for 10 min in a kinase buffer containing 50 mM Tris–HCl,pH 7.5, 0.5 mM CaCl 2, 5 mM magnesium acetate, 25 μg/mL phosphatidyl serine, 50 ng/mL 12–O–tetradecanoylphorbol–13–acetate and 0.001% leupeptin in a total volume of 30 μL. Incubation is terminated by the addition of 10 μL of 43 Laemmli sample buffer.After boiling for 5 min, the mixture is subjected to SDS–polyacrylamide gel electrophoresis on a 16% gel. The gel is stained withCoomassie Brilliant Blue, and then dried. The bands corresponding to histone type 2 are excised, and the radioactivity is measured [1]. Cell Assay: Y–27632 is dissolved in water and stored [1].[1]HeLa cells are plated at a density of 3×104 cells per 3.5–cm dish. The cells are cultured in DMEM containing 10% FBS in the presence of 10 mM Thymidine for 16 h. After the cells are washed with DMEM containing 10% FBS, they are cultured for an additional 8 h, and then 40 ng/mL of Nocodazole is added. After 11.5 h of theNocodazole treatment, various concentrations of Y–27632 (0–300 μM), Y–30141, or vehicle is added and the cells are incubated for another 30 min [1].Animal Administration: Y–27632 is dissolved in 0.9% NaCl (saline) (Mice)[3].Product Name:Y–27632Cat. No.:HY-10071CAS No.:146986-50-7Molecular Formula:C 14H 21N 3O Molecular Weight:247.34Target:ROCK; ROCK; ROCK Pathway:TGF–beta/Smad; Stem Cell/Wnt; Cell Cycle/DNA Damage Solubility:DMSO: ≥ 32 mg/mLY–27632 is dissolved in saline (final concentration 2%) (Rat)[4].[3][4]Mice[3]Male, inbred Swiss albino mice (2–3 months old) weighing 25–30 g are used. Mice are injected with a sub–convulsive dose of PTZ (35 mg/kg, i.p.) (on Mondays, Wednesdays and Fridays) of each week for a total of 11 injections. After each PTZ injection, mice are observed for 30 min and the occurrence of convulsive activity is recorded. After 30 min, the mice are then injected with either Fasudil (25 mg/kg, i.p.) or Y–27632 (5 mg/kg, i.p.) and returned to their home cages until the next injection. Control mice for Fasudil andY–27632 receives saline.Rat[4]Male Wistar Kind A rats (200–250 g) are used. DMN (1 g/mL) is diluted ten times with saline (final concentration 1%) and 10 mg/kg per day of DMN is injected intraperitoneally (i.p.) on the first 3 days of each week for 4 weeks. Y27632 is given orally once per day at a dose of 30 mg/kg for 4 weeks starting on the day of the first injection of DMN. The dose of 30 mg/kg corrects hypertension in several rat models without toxicity. Twenty rats are randomized into four experimental groups (n=5 in each group) as follows: (1) S–S (injection of saline i.p. and oral administration of saline); (2) S–Y (injection of saline i.p. and oral administration of Y27632); (3) DMN–S (DMN i.p. and oral administration of saline); (4) DMN–Y (DMN i.p. and oral administration of Y27632). The rats are weighed every week. They are sacrificed at the end of the fourth week and the liver is excised. In addition, a blood sample is taken immediately before the rats are sacrificed.References:[1]. Ishizaki T, et al. Pharmacological properties of Y–27632, a specific inhibitor of rho–associated kinases. Mol Pharmacol. 2000 May;57(5):976–83.[2]. Xue ZW, et al. Rho–associated coiled kinase inhibitor Y–27632 promotes neuronal–like differentiation of adult human adipose tissue–derived stem cells.Chin Med J (Engl). 2012 Sep;125(18):3332–5.[3]. Inan S, et al. Antiepileptic effects of two Rho–kinase inhibitors, Y–27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44–51.[4]. Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine–induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529–36.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
Sigma-Aldrich实验室常用生化试剂大促销
缓冲液
产品货号 英文品名 中文品名 优惠价 (R M B ) 目录价 (RMB)
A1542-2.5KG A1542-250G A1542-500G B7901-1KG B7901-500G C3041-100CAP C3041-50CAP C3674-100G C3674-1KG C3674-500G E9508-100ML E9508-10UL E9508-1L E9508-2.5L E9508-500ML E6758-100G E6758-500G H3375-100G H3375-1KG H3375-250G H3375-25G H3375-500G H3375-5KG I0125-100G I0125-10G I0125-1KG I0125-25G I0125-500G I0125-5KG M2933-100G M2933-1KG M2933-25G M2933-500G M1254-100G M1254-1KG M1254-250G M1254-25G M1254-50KG M1254-5KG P5493-1L P5493-4L P4809-100TAB P4809-50TAB
Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose Agarose
低熔点琼脂糖 低熔点琼脂糖 低熔点琼脂糖 低熔点琼脂糖 低熔点琼脂糖 低熔点琼脂糖 琼脂糖 琼脂糖 琼脂糖 琼脂糖 琼脂糖 琼脂糖
Ammonium acetate ~98% Ammonium acetate ~98% Ammonium acetate ~98% Boric acid Boric acid Carbonate-Bicarbonate Buffer Carbonate-Bicarbonate Buffer Citric acid trisodium salt Citric acid trisodium salt Citric acid trisodium salt Ethanolamine >=98% Ethanolamine >=98% Ethanolamine >=98% Ethanolamine >=98% Ethanolamine >=98% Ethylenediaminetetraacetic acid >=98.5% Ethylenediaminetetraacetic acid >=98.5% HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) HEPES >=99.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) Imidazole >=98.5% (titration) MES hydrate >=99.5% MES hydrate >=99.5% MES hydrate >=99.5% MES hydrate >=99.5% MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) MOPS >=99.5% (titration) Phosphate buffered saline Phosphate buffered saline Phosphate-Citrate Buffer Phosphate-Citrate Buffer
GC-MSMS法测定阿莫西林原料药中12种N-亚硝胺类基因毒性杂质
收稿日期：2020-12-08作者简介：周刚，男，生于1980年，硕士，副主任药师，E-mail:********************通讯作者，E-mail:***************文章编号：1001-8689(2021)04-0291-06第一作者：周刚，男，中国药科大学药物分析学硕士，就职于内蒙古自治区药品检验研究院化学药品室主任，从事化学药品(抗生素)检验及质量研究与评价工作，参与完成多项国家级、省部级科研项目。
通讯作者：高家敏，女，生于1981年，中国食品药物检定研究院药物分析学硕士，副主任药师，就职于中国食品药品检定研究院，从事药品化妆品检测与安全评价工作，参与多项国家级科研项目。
GC-MS/MS 法测定阿莫西林原料药中12种N-亚硝胺类基因毒性杂质周刚1 李鹏飞1 高家敏2,*(1 内蒙古自治区药品检验研究院，呼和浩特 010020；2 中国食品药品检定研究院，北京 100050)摘要：目的 采用GC-MS/MS 法，建立阿莫西林原料药中12种N-亚硝胺类化合物含量测定的方法。
方法 样品经二氯甲烷提取后，涡旋、离心、取上清液过滤，采用VF-WAXms(30m ×0.25mm ×0.25μm)毛细管气相色谱柱分离，选择性反应监测(SRM)进行定性定量检测。
结果 12种N-亚硝胺在0.5~200ng/mL 浓度范围内线性关系良好，相关系数均在0.998以上；检测限为0.033~0.481ng/mL ，定量限为0.110~1.604ng/mL ；回收率在78.5%~106.6%之间。
结论 所建立的GC-MS/MS 测定法专属性好、灵敏度高，可同时测定12种N-亚硝胺杂质，为阿莫西林原料药中基因毒性杂质的质量控制提供参考。
关键词：阿莫西林；N-亚硝胺类基因毒性杂质；GC-MS/MS 中图分类号：R978.1 文献标志码：ADetermination of N-nitrosamines 12 kinds of genotoxic impuritiesin amoxicillin API by GC-MS/MSZhou Gang 1, Li Peng-fei 1, and Gao Jia-min 2(1 Inner Mongolia Institutes for Drug Control, Hohhot 010020; 2 National Institutes for Food and Drug Control, Beijing 100050)Abstract Objective A GC-MS/MS method was developed for the determination of 12 kinds of N-nitrosamines in amoxicillin API. Methods The sample was extracted by dichloromethane, and the supernatant was filtered. The sample was separated by a VF WAXms (30m×0.25mm×0.25μm) capillary gas chromatography column, and the selection reaction monitoring (SRM) was selected for the qualitative and quantitative detection. Results The linear range of N-nitrosamines was 0.5~200ng/mL, and the correlation coeffi cients were all above 0.998; the detection limits were 0.033~0.481ng/mL; the limits of quantification were 0.110~1.604ng/mL; the recoveries were between 78.5% and 106.6%. Conclusion The established GC-MS/MS method has good specificity and high sensitivity. The method can simultaneously determine 12 kinds of N-nitrosamine impurities, which provides a reference for the quality control of genotoxic impurities in amoxicillin API.Key words Amoxicillin; N-nitrosamines genotoxic impurities; GC-MS/MS基因毒性是Ashby等[1]在1991年首次提出的概念，基于300多种化合物对DNA活性影响的研究成果，将其定义为经过适当遗传毒性实验模型，如细菌基因突变(Ames)实验，证实具有遗传毒性的杂质。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Product Name:
Amsacrine CAS No.:
51264-14-3Cat. No.:
HY-13551Product Data Sheet
MWt:
393.46Formula:
C21H19N3O3S Purity :>98%
DMSO
Solubility:Mechanisms:
Biological Activity:
A i (AMSA)ti l ti t hi h i t l t i t th DNA f t ll
Pathways:Cell Cycle/DNA Damage; Target:Topoisomerase Amsacrine (mAMSA) an antineoplastic agent which can intercalate into the DNA of tumor cells. Amsacrine also expresses topoisomerase inhibitor activity, specifically inhibiting topoisomerase II.
IC50 value:
Target: DNA intercalator; Topo II in vitro: Amsacrine attenuated cell invasion with decreased MMP-2/MMP-9 protein expression and mRNA levels in U937, Jurkat, HL-60, K562, KU812 and MEG-01 cells. Moreover, amsacrine reduced both MMP-2/MMP-9 promoter luciferase activity and MMP-2/MMP-9 mRNA stability in leukemia cells.Studies on amsacrine-treated U937 cells revealed that amsacrine-elicited ROS
generation induced JNK and p38MAPK activation but reduced the phospho-ERK level.Amsacrine-References:
[1]. Kanellis J, et al. JNK signalling in human and experimental renal ischaemia/reperfusion injury.Nephrol Dial Transplant 2010Sep;25(9):2898908generation induced JNK and p38 MAPK activation but reduced the phospho ERK level. Amsacrine induced ERK inactivation and p38 MAPK/JNK activation were demonstrated to suppress MMP-2/MMP-9 promoter luciferase activity and promote MMP-2/MMP-9 mRNA decay, respectively [1].Amsacrin...
Nephrol Dial Transplant. 2010 Sep;25(9):2898-908.
[2]. Thomas D, et al. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor
amsacrine: mode of action. Br J Pharmacol. 2004 Jun;142(3):485-94.[3]. Attia SM. Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine
and nocodazole in mouse bone marrow cells. J Appl Toxicol. 2013 Jun;33(6):426-33.[4]. Kao-Shan CS, et al. Cytogenetic effects of amsacrine on human lymphocytes in vivo and in vitro.
Cancer Treat Rep. 1984 Jul-Aug;68(7-8):989-97.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。